

# Epidemiology of Primary Liver Cancer

Seminars in Liver Disease

19, 271-285

DOI: [10.1055/s-2007-1007117](https://doi.org/10.1055/s-2007-1007117)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases. <i>Oncology Reports</i> , 1994, 20, 863.	2.6	8
2	PUBLIC HEALTH:Reducing Liver Cancer--Global Control of Aflatoxin. <i>Science</i> , 1999, 286, 2453-2454.	12.6	215
3	Liver metastases: new approaches to a difficult challenge. <i>Journal of Surgical Education</i> , 2000, 57, 3-7.	0.7	0
4	Early diagnosis and treatment of hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2000, 14, 991-1008.	2.4	45
5	Epidemiology of Liver Cancer in Europe. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2000, 14, 621-630.	1.7	35
6	Evolution of Cancer Epidemiology. <i>Epidemiologic Reviews</i> , 2000, 22, 35-56.	3.5	17
7	Modulation of Glutathione S-Transferase Alpha by Hepatitis B Virus and the Chemopreventive Drug Oltipraz. <i>Journal of Biological Chemistry</i> , 2000, 275, 33395-33403.	3.4	27
8	Radiofrequency ablation in the treatment of hepatocellular carcinoma - a clinical viewpoint. <i>Journal of Hepatology</i> , 2000, 33, 667-672.	3.7	39
9	Hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2000, 32, 225-237.	3.7	452
10	Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference. <i>Journal of Hepatology</i> , 2001, 35, 421-430.	3.7	3,959
11	Tratamiento quirúrgico del hepatocarcinoma en el paciente cirrótico: ¿resección o trasplante?. <i>Cirugía Española</i> , 2001, 70, 42-48.	0.2	5
12	A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2001, 37, 1352-1358.	2.8	23
15	A Proteomic Approach for the Discovery of Early Detection Markers of Hepatocellular Carcinoma. <i>Disease Markers</i> , 2001, 17, 179-189.	1.3	54
16	Inheritance of Resistance to Promotion of Preneoplastic Liver Lesions in Copenhagen Rats. <i>Experimental Biology and Medicine</i> , 2001, 226, 831-835.	2.4	7
17	Liver Cancer in Atomic-bomb Survivors: Histological Characteristics and Relationships to Radiation and Hepatitis B and C Viruses. <i>Journal of Radiation Research</i> , 2001, 42, 117-130.	1.6	21
18	Radiofrequency Thermal Ablation of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2001, 19, 301-310.	1.9	19
19	Hepatocellular Carcinoma: An Asian Perspective. <i>Digestive Diseases</i> , 2001, 19, 263-268.	1.9	69
20	Different clinicopathological features of hepatocellular carcinoma in relation to causative agents. <i>Journal of Gastroenterology</i> , 2001, 36, 73-78.	5.1	21

#	ARTICLE	IF	CITATIONS
21	Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with non-€irrhotic and cirrhotic chronic viral hepatitis. <i>Histopathology</i> , 2001, 39, 66-73.	2.9	96
22	Hepatocellular carcinoma: an overview. <i>Histopathology</i> , 2001, 39, 109-118.	2.9	112
23	Risk factors for hepatocellular carcinoma in Turkey. <i>Digestive Diseases and Sciences</i> , 2001, 46, 1022-1028.	2.3	55
24	Expression profiling and identification of novel genes in hepatocellular carcinomas. <i>Oncogene</i> , 2001, 20, 2704-2712.	5.9	85
25	The epidemiology and prevention of hepatocellular carcinoma. <i>Seminars in Oncology</i> , 2001, 28, 441-449.	2.2	120
26	Management of hepatocellular carcinoma: advances in diagnosis, treatment and prevention. <i>Expert Review of Anticancer Therapy</i> , 2001, 1, 277-290.	2.4	23
27	Genetic polymorphisms of glutathione S-transferases M1 and T1 associated with susceptibility to aflatoxin-related hepatocarcinogenesis among chronic hepatitis B carriers: a nested case-control study in Taiwan. <i>Carcinogenesis</i> , 2001, 22, 1289-1294.	2.8	93
28	The epidemiology of primary liver cancer: global epidemiology. <i>Perspectives in Medical Virology</i> , 2002, , 1-16.	0.1	10
29	Upstream binding factor up-€regulated in hepatocellular carcinoma is related to the survival and cisplatin-€sensitivity of cancer cells. <i>FASEB Journal</i> , 2002, 16, 293-301.	0.5	41
30	DNA Methylation and Environmental Exposures in Human Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2002, 94, 755-761.	6.3	225
31	Does diabetes mellitus influence the perioperative outcome or long term prognosis after resection of hepatocellular carcinoma?. <i>American Journal of Gastroenterology</i> , 2002, 97, 1480-1488.	0.4	53
32	Combined in vitro anti-tumoral action of tamoxifen and retinoic acid derivatives in hepatoma cells. <i>International Journal of Oncology</i> , 2002, 20, 89-96.	3.3	9
33	Treatment of hepatocellular carcinoma. <i>Perspectives in Medical Virology</i> , 2002, , 161-172.	0.1	1
34	Hepatitis viruses and hepatocellular carcinoma in HIV-infected patients. <i>Current Opinion in Oncology</i> , 2002, 14, 538-542.	2.4	22
35	Hepatocellular carcinoma. <i>Current Opinion in Gastroenterology</i> , 2002, 18, 345-350.	2.3	2
36	Tobacco smoking- and alcohol drinking-attributable cancer mortality in Germany. <i>European Journal of Cancer Prevention</i> , 2002, 11, 11-17.	1.3	50
37	Locoregional Therapies for Hepatocellular Carcinoma: A Critical Review From the Surgeon-€s Perspective. <i>Annals of Surgery</i> , 2002, 235, 466-486.	4.2	374
38	Interferon for the prevention of hepatocellular carcinoma. <i>Perspectives in Medical Virology</i> , 2002, 6, 151-159.	0.1	0

#	ARTICLE	IF	CITATIONS
39	Clinical relevance of hepatocyte proliferative activity. <i>Digestive and Liver Disease</i> , 2002, 34, 174-176.	0.9	0
40	Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. <i>Gastroenterology</i> , 2002, 123, 134-140.	1.3	1,332
41	Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. <i>Lancet, The</i> , 2002, 359, 1734-1739.	13.7	3,172
42	Gray-scale ultrasound in hepatic cirrhosis and chronic hepatitis: Diagnosis, screening, and intervention. <i>Seminars in Ultrasound, CT and MRI</i> , 2002, 23, 3-18.	1.5	43
43	Why can't Chinese Han drink alcohol? Hepatitis B virus infection and the evolution of acetaldehyde dehydrogenase deficiency. <i>Medical Hypotheses</i> , 2002, 59, 204-207.	1.5	28
44	Epidemiology and Clinical Presentation of Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2002, 13, S169-S171.	0.5	86
45	Expression of the lung resistance-related protein in human and rat hepatocarcinogenesis. <i>American Journal of Physiology - Renal Physiology</i> , 2002, 283, G1117-G1124.	3.4	17
46	Radiofrequency thermal ablation for treatment of hepatocellular carcinoma. <i>International Journal of Clinical Oncology</i> , 2002, 7, 225-235.	2.2	18
47	Prognosis of a large cohort of patients with hepatocellular carcinoma in a single European centre. <i>Liver</i> , 2002, 22, 23-28.	0.1	39
49	Evidence-based medicine in the treatment of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, S428-S433.	2.8	12
50	Epidemiology of hepatocellular carcinoma. <i>Toxicology</i> , 2002, 181-182, 35-38.	4.2	95
51	Different expression of hepatitis B surface antigen between hepatocellular carcinoma and its surrounding liver tissue, studied using a tissue microarray. <i>Journal of Pathology</i> , 2002, 197, 610-616.	4.5	44
52	New targets of $\beta$ -catenin signaling in the liver are involved in the glutamine metabolism. <i>Oncogene</i> , 2002, 21, 8293-8301.	5.9	366
53	Molecular pathogenesis of human hepatocellular carcinoma. <i>Nature Genetics</i> , 2002, 31, 339-346.	21.4	1,327
54	Focal lesions in cirrhotic explant livers: Pathological evaluation and accuracy of pretransplantation imaging examinations. <i>Liver Transplantation</i> , 2002, 8, 749-761.	2.4	206
55	Detection of mutant p53 in hepatocellular cancer from Turkey and its correlation with clinicopathologic parameters. <i>Digestive Diseases and Sciences</i> , 2003, 48, 865-869.	2.3	1
56	Interferon- $\gamma$ Is More Potent Than Interferon- $\alpha$ in Inhibition of Human Hepatocellular Carcinoma Cell Growth When Used Alone and in Combination With Anticancer Drugs. <i>Annals of Surgical Oncology</i> , 2003, 10, 1184-1190.	1.5	68
57	HCC surveillance: Who is the target population?. <i>Hepatology</i> , 2003, 37, 507-509.	7.3	46

#	ARTICLE	IF	CITATIONS
58	Overexpression of a novel imprinted gene, PEG10, in human hepatocellular carcinoma and in regenerating mouse livers. <i>Journal of Biomedical Science</i> , 2003, 10, 625-635.	7.0	9
59	Treatment of hepatocellular carcinoma. <i>Current Treatment Options in Gastroenterology</i> , 2003, 6, 465-472.	0.8	13
60	Screening for hepatocellular carcinoma: Why, when, how?. <i>Current Gastroenterology Reports</i> , 2003, 5, 57-62.	2.5	4
61	Association of over-expressed TFDP1 with progression of hepatocellular carcinomas. <i>Journal of Human Genetics</i> , 2003, 48, 609-613.	2.3	47
62	Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. <i>Journal of the American College of Surgeons</i> , 2003, 197, 759-764.	0.5	116
63	Impact of N-acetyltransferase polymorphism (NAT2) in hepatocellular carcinoma (HCC) – an investigation in a department of surgical medicine. <i>Experimental and Toxicologic Pathology</i> , 2003, 54, 387-391.	2.1	13
64	Hepatic radiofrequency ablation with internally cooled probes: effect of coolant temperature on lesion size. <i>IEEE Transactions on Biomedical Engineering</i> , 2003, 50, 493-500.	4.2	136
65	Cancer Statistics for Hispanics, 2003. <i>Ca-A Cancer Journal for Clinicians</i> , 2003, 53, 208-226.	329.8	123
66	Etiology, natural history and treatment of hepatocellular carcinoma. <i>Antiviral Research</i> , 2003, 60, 145-150.	4.1	64
67	Hepatocellular carcinoma among atomic bomb survivors: Significant interaction of radiation with hepatitis C virus infections. <i>International Journal of Cancer</i> , 2003, 103, 531-537.	5.1	32
68	Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. <i>International Journal of Cancer</i> , 2003, 105, 724-732.	5.1	83
69	Contrast-enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation. <i>Journal of Clinical Ultrasound</i> , 2003, 31, 119-128.	0.8	28
70	Hepatocellular carcinoma: surgical indications and results. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 47, 13-27.	4.4	70
71	Chronic viral hepatitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2003, 17, 259-275.	2.4	17
72	Thermal ablative therapy for malignant liver tumors: A critical appraisal. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 616-629.	2.8	61
73	Changing relative roles of hepatitis B and C viruses in the aetiology of hepatocellular carcinoma in Greece. Epidemiological and clinical observations. <i>Journal of Viral Hepatitis</i> , 2003, 10, 450-454.	2.0	21
74	Liver resection for hepatocellular carcinoma in cirrhotics and noncirrhotics. Evaluation of clinicopathologic features and comparison of risk factors for long-term survival and tumour recurrence in a single centre. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 119-129.	3.7	101
75	Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatm. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 1563-1569.	3.7	45

#	ARTICLE	IF	CITATIONS
76	A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. <i>Proteomics</i> , 2003, 3, 601-609.	2.2	157
77	Transgenic mouse models of hepatitis B virus-associated hepatocellular carcinoma. <i>Reviews in Medical Virology</i> , 2003, 13, 243-253.	8.3	40
78	Identification of a novel cell cycle regulated gene, HURP, overexpressed in human hepatocellular carcinoma. <i>Oncogene</i> , 2003, 22, 298-307.	5.9	134
79	Identification and characterization of CRG-L2, a new marker for liver tumor development. <i>Oncogene</i> , 2003, 22, 1730-1736.	5.9	19
80	Sustained hepatic expression of FoxM1B in transgenic mice has minimal effects on hepatocellular carcinoma development but increases cell proliferation rates in preneoplastic and early neoplastic lesions. <i>Oncogene</i> , 2003, 22, 6266-6276.	5.9	44
81	What surgeons should know about viral hepatitis and hepatocellular carcinoma. <i>Surgical Oncology Clinics of North America</i> , 2003, 12, 1-11.	1.5	1
82	Treatment of hepatocellular carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 10-18.	4.4	31
83	Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after hepatic resection in Chinese patients. <i>Surgical Oncology Clinics of North America</i> , 2003, 12, 35-50.	1.5	97
84	Diabetes Mellitus Is A Risk Factor for Hepatic Decompensation in Patients With Hepatocellular Carcinoma Undergoing Resection: A Longitudinal Study. <i>American Journal of Gastroenterology</i> , 2003, 98, 2293-2298.	0.4	63
85	Aberrant CpG Island Hypermethylation Along Multistep Hepatocarcinogenesis. <i>American Journal of Pathology</i> , 2003, 163, 1371-1378.	3.8	301
86	European Code Against Cancer and scientific justification: third version (2003). <i>Annals of Oncology</i> , 2003, 14, 973-1005.	1.2	247
87	Identification of liverâ€œintestine cadherin in hepatocellular carcinomaâ€œa potential disease marker. <i>Biochemical and Biophysical Research Communications</i> , 2003, 311, 618-624.	2.1	75
88	Hepatocellular carcinoma: present status and future prospects. <i>Journal of Hepatology</i> , 2003, 38, 136-149.	3.7	205
89	Liver transplantation for hepatocellular carcinoma in cirrhotic patients. <i>Transplantation Proceedings</i> , 2003, 35, 1827-1829.	0.6	26
90	Hepatitis B virus and hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2003, 39, 59-63.	3.7	87
91	Spiral computed tomography versus ultrasound in the follow-up of cirrhotic patients previously treated for hepatocellular carcinoma: a prospective study. <i>Journal of Hepatology</i> , 2003, 39, 93-98.	3.7	13
92	Hepatocellular carcinoma. <i>Lancet, The</i> , 2003, 362, 1907-1917.	13.7	3,886
94	Long-Term Disease-Free Survival After Resection of Hepatocellular Carcinoma: Both Tumor Behavior and Surgeonâ€™s Performance Are Important Determinants. <i>Annals of Surgical Oncology</i> , 2003, 10, 834-836.	1.5	8

#	ARTICLE	IF	CITATIONS
95	Overexpression of a Novel Imprinted Gene, <i>PEG10</i> , in Human Hepatocellular Carcinoma and in Regenerating Mouse Livers. <i>Journal of Biomedical Science</i> , 2003, 10, 625-635.	7.0	63
96	Liver Cancer: An Overview. <i>Cancer Reviews: Asia-Pacific</i> , 2003, 01, 297-311.	0.1	0
97	Twenty-year trends of primary liver cancer incidence rates in an urban Chinese population. <i>European Journal of Cancer Prevention</i> , 2003, 12, 273-279.	1.3	31
98	Title is missing!. <i>Annals of Surgery</i> , 2003, 237, 536-543.	4.2	33
99	Safe radiation exposure of medical personnel by using simple methods of radioprotection while administering <sup>131</sup> I-iodine therapy for hepatocellular carcinoma. <i>Nuclear Medicine Communications</i> , 2003, 24, 671-678.	1.1	15
100	Hepatocellular carcinoma. <i>Current Opinion in Gastroenterology</i> , 2003, 19, 243-249.	2.3	11
101	Liver Resection for Hepatocellular Carcinoma on Cirrhosis. <i>Annals of Surgery</i> , 2003, 237, 536-543.	4.2	312
103	Value of Live Donor Liver Transplantation Experience in Major Hepatectomy for Hepatocellular Carcinoma. <i>Archives of Surgery</i> , 2003, 138, 265.	2.2	17
104	Epidemiologie und Klinik des hepatozellulären Karzinoms. <i>Visceral Medicine</i> , 2003, 19, 214-217.	1.3	0
105	Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C virus. <i>Arquivos De Gastroenterologia</i> , 2004, 41, 180-184.	0.8	36
107	CD80 transfected human hepatocellular carcinoma cells activate cytotoxic T lymphocytes to target HCC cells with shared tumor antigens. <i>Oncology Reports</i> , 2004, 12, 435.	2.6	1
108	Diagnosis, staging and treatment of hepatocellular carcinoma. <i>Brazilian Journal of Medical and Biological Research</i> , 2004, 37, 1689-1705.	1.5	75
109	An Update on the Molecular Genetics of Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2004, 24, 77-88.	3.6	88
110	Pretransplantation Diagnosis and Staging of Hepatocellular Carcinoma in Patients with Cirrhosis: Value of Dual-Phase Helical CT. <i>American Journal of Roentgenology</i> , 2004, 182, 1011-1017.	2.2	88
111	Unusual Sites of Metastatic Involvement. <i>Journal of Clinical Oncology</i> , 2004, 22, 1156-1157.	1.6	6
112	Clinical Significance of Thrombospondin 1 Expression in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 4150-4157.	7.0	94
113	Predictive Value of Biological Markers for Hepatocellular Carcinoma Patients Treated with Orthotopic Liver Transplantation. <i>Clinical Cancer Research</i> , 2004, 10, 1789-1795.	7.0	48
114	Prognostic Impact of Diabetes Mellitus on Patients with Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2004, 99, 1488-1489.	0.4	1

#	ARTICLE	IF	CITATIONS
115	p16INK4A Gene alterations are not a prognostic indicator for survival in patients with hepatocellular carcinoma undergoing curative hepatectomy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 397-405.	2.8	17
116	Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 779-788.	3.7	109
117	Preoperative assessment of liver function: a comparison of <sup>99m</sup> Tc-Mebrofenin scintigraphy with indocyanine green clearance test. <i>Liver International</i> , 2004, 24, 117-123.	3.9	7,546
118	A ginseng saponin metabolite-induced apoptosis in HepG2 cells involves a mitochondria-mediated pathway and its downstream caspase-8 activation and Bid cleavage. <i>Toxicology and Applied Pharmacology</i> , 2004, 194, 221-229.	2.8	72
120	Cancer Disparities by Race/Ethnicity and Socioeconomic Status. <i>Ca-A Cancer Journal for Clinicians</i> , 2004, 54, 78-93.	329.8	1,404
121	Current status of radio-frequency ablation for hepatocellular carcinoma. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2004, 36, 322-330.	0.7	2
122	Deterioration of Hepatic Functional Reserve in Patients with Hepatocellular Carcinoma after Resection: Incidence, Risk Factors, and Association with Intrahepatic Tumor Recurrence. <i>World Journal of Surgery</i> , 2004, 28, 258-262.	1.6	28
123	Development and biodistribution of <sup>188</sup> Re-SSS lipiodol following injection into the hepatic artery of healthy pigs. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 542-546.	6.4	31
124	Hepatocellular carcinoma: Updates in primary prevention. <i>Current Gastroenterology Reports</i> , 2004, 6, 37-43.	2.5	7
125	Natural history of chronic hepatitis B. <i>Current Hepatitis Reports</i> , 2004, 3, 54-60.	0.3	2
126	Integration of woodchuck hepatitis and N-myc rearrangement determine size and histologic grade of hepatic tumors. <i>Hepatology</i> , 2004, 39, 1008-1016.	7.3	50
127	Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. <i>Hepatology</i> , 2004, 39, 1038-1047.	7.3	192
128	Identification of the leukocyte cell-derived chemotaxin 2 as a direct target gene of $\beta$ -catenin in the liver. <i>Hepatology</i> , 2004, 40, 167-176.	7.3	103
129	Hepatocellular carcinoma and liver tumors in South African children. <i>Cancer</i> , 2004, 101, 642-649.	4.1	50
130	Cancer mortality in Europe, 1995-1999, and an overview of trends since 1960. <i>International Journal of Cancer</i> , 2004, 110, 155-169.	5.1	170
131	Polygenic control of hepatocarcinogenesis in Copenhagen Å— F344 rats. <i>International Journal of Cancer</i> , 2004, 111, 9-16.	5.1	26
132	Hepatectomy for hepatocellular carcinoma: Patient selection and postoperative outcome. <i>Liver Transplantation</i> , 2004, 10, S39-S45.	2.4	181
133	Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: Outcome with chemoembolization. <i>Liver Transplantation</i> , 2004, 10, 449-455.	2.4	195



#	ARTICLE	IF	CITATIONS
134	The development of <i>de novo</i> hepatocellular carcinoma in patients on a liver transplant list: Frequency, size, and assessment of current screening methods. <i>Liver Transplantation</i> , 2004, 10, 631-637.	2.4	34
135	Comparison of the expression of $\beta$ -catenin in hepatocellular carcinoma in areas with high and low levels of exposure to aflatoxin B1. <i>Journal of Surgical Oncology</i> , 2004, 86, 157-163.	1.7	18
136	Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. <i>Journal of Gastrointestinal Surgery</i> , 2004, 8, 200-207.	1.7	30
137	The influence on liver parenchymal function and complications of radiofrequency ablation or the combination with transcatheter arterial embolization for hepatocellular carcinoma. <i>Hepatology Research</i> , 2004, 29, 18-23.	3.4	32
138	Patterns of methylation profiles as diagnostic markers for multiple hepatocellular carcinomas. <i>Scandinavian Journal of Gastroenterology</i> , 2004, 39, 246-251.	1.5	7
139	Hepatomaâ€”resection or transplantation. <i>Surgical Clinics of North America</i> , 2004, 84, 495-511.	1.5	18
140	Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. <i>Gastroenterology</i> , 2004, 126, 102-110.	1.3	389
141	Primary liver cancer: Worldwide incidence and trends. <i>Gastroenterology</i> , 2004, 127, S5-S16.	1.3	2,193
142	Hepatocellular carcinoma: Recent trends in Japan. <i>Gastroenterology</i> , 2004, 127, S17-S26.	1.3	275
143	Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. <i>Gastroenterology</i> , 2004, 127, S35-S50.	1.3	2,168
144	High-Dose proton beam radiotherapy of hepatocellular carcinoma: Preliminary results of a phase II trial. <i>Gastroenterology</i> , 2004, 127, S189-S193.	1.3	134
145	Hepatocellular carcinoma: Summary and recommendations. <i>Gastroenterology</i> , 2004, 127, S319-S323.	1.3	45
146	Therapeutic Options in Hepatocellular Carcinoma. <i>American Journal of Cancer</i> , 2004, 3, 119-131.	0.4	2
147	Fatal Pulmonary Complications after Arterial Embolization with 40â€”120- $\mu$ m Tris-acryl Gelatin Microspheres. <i>Journal of Vascular and Interventional Radiology</i> , 2004, 15, 197-200.	0.5	110
148	Ultrasound-guided percutaneous thermal ablation of hepatocellular carcinoma using microwave and radiofrequency ablation. <i>Clinical Radiology</i> , 2004, 59, 53-61.	1.1	104
149	Hepatocellular carcinoma. <i>Disease-a-Month</i> , 2004, 50, 556-573.	1.1	27
150	Expression of hepatitis C virus core protein impairs DNA repair in human hepatoma cells. <i>Cancer Letters</i> , 2004, 209, 197-205.	7.2	26
151	Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2004, 315, 950-958.	2.1	143

#	ARTICLE	IF	CITATIONS
152	Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2004, 41, 999-1007.	3.7	39
154	<sup>188</sup> Re-SSS lipiodol: radiolabelling and biodistribution following injection into the hepatic artery of rats bearing hepatoma. <i>Nuclear Medicine Communications</i> , 2004, 25, 1007-1013.	1.1	31
155	p14ARF gene alterations in human hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 19-26.	1.6	23
156	Time trends in incidence and mortality for chronic liver disease and liver cancer in the interval 1980-1997 in Catalonia, Spain. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 865-872.	1.6	15
157	Caveolin and Thrombospondin Expression During Hepatocellular Carcinogenesis. <i>American Journal of Surgical Pathology</i> , 2004, 28, 357-364.	3.7	28
158	Development of <sup>99m</sup> Tc labelled Lipiodol: biodistribution following injection into the hepatic artery of the healthy pig. <i>Nuclear Medicine Communications</i> , 2004, 25, 291-297.	1.1	14
159	Circulating Messenger RNA of $\alpha$ -Fetoprotein. <i>Archives of Surgery</i> , 2004, 139, 1055.	2.2	22
160	Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma. , 2004, , CD003046.		31
161	Cytohistologic Correlation of Cirrhosis and Hepatocellular Carcinoma. <i>Acta Cytologica</i> , 2004, 48, 127-132.	1.3	19
162	Identification of a Unique Gene Expression Signature That Differentiates Hepatocellular Adenoma From Well-Differentiated Hepatocellular Carcinoma. <i>American Journal of Surgical Pathology</i> , 2005, 29, 1600-1608.	3.7	32
163	Comparing the Outcomes of Radiofrequency Ablation and Surgery in Patients With a Single Small Hepatocellular Carcinoma and Well-Preserved Hepatic Function. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, 247-252.	2.2	227
164	Hepatocellular carcinoma. <i>Current Opinion in Gastroenterology</i> , 2005, 21, 308-312.	2.3	34
165	The surveillance and diagnosis of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 491-496.	1.6	23
166	Clinical presentation and natural course of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 485-489.	1.6	48
167	Significant Long-Term Survival After Radiofrequency Ablation of Unresectable Hepatocellular Carcinoma in Patients with Cirrhosis. <i>Annals of Surgical Oncology</i> , 2005, 12, 616-628.	1.5	152
168	Prevention of hepatocellular carcinoma. <i>Hpb</i> , 2005, 7, 16-25.	0.3	9
169	Chinese Herbal Medicine and Chemotherapy in the Treatment of Hepatocellular Carcinoma: A Meta-analysis of Randomized Controlled Trials. <i>Integrative Cancer Therapies</i> , 2005, 4, 219-229.	2.0	71
170	Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area. <i>Liver International</i> , 2005, 25, 236-241.	3.9	63

#	ARTICLE	IF	CITATIONS
171	Resection of Hepatocellular Carcinoma in Noncirrhotic Liver: Analysis of Risk Factors for Survival. <i>Journal of the American College of Surgeons</i> , 2005, 201, 663-670.	0.5	80
172	SCCA antigen combined with alpha-fetoprotein as serologic markers of HCC. <i>International Journal of Cancer</i> , 2005, 117, 506-509.	5.1	58
173	Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma. <i>Cancer</i> , 2005, 103, 299-306.	4.1	160
174	Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. <i>Cancer</i> , 2005, 104, 794-801.	4.1	99
175	Fatigue patterns and correlates in male liver cancer patients receiving transcatheter hepatic arterial chemoembolization. <i>Supportive Care in Cancer</i> , 2005, 13, 311-317.	2.2	30
176	Clinicopathological features of hepatocellular carcinomas (HCCs) arising in patients without chronic viral infection or alcohol abuse: a retrospective study of patients undergoing hepatic resection. <i>Journal of Gastroenterology</i> , 2005, 40, 274-282.	5.1	22
177	Early liver cancer: concepts, diagnosis, and management. <i>International Journal of Clinical Oncology</i> , 2005, 10, 384-390.	2.2	6
178	Current approaches to the diagnosis and management of hepatocellular carcinoma. <i>Clinical and Experimental Medicine</i> , 2005, 5, 1-13.	3.6	16
179	Determination of High Mobility Group A1 (HMGA1) Expression in Hepatocellular Carcinoma: A Potential Prognostic Marker. <i>Digestive Diseases and Sciences</i> , 2005, 50, 1764-1770.	2.3	48
180	Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment. <i>Proteomics</i> , 2005, 5, 4287-4295.	2.2	55
181	Oxidation of specific methionine and tryptophan residues of apolipoprotein A-I in hepatocarcinogenesis. <i>Proteomics</i> , 2005, 5, 4964-4972.	2.2	30
182	Usefulness of serum des-Î³-carboxy prothrombin in detection of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2005, 11, 6115.	3.3	83
184	Epidemiology and Prevention of Hepatitis B Virus Infection. <i>International Journal of Medical Sciences</i> , 2005, 2, 50-57.	2.5	310
185	Screening for Hepatocellular Carcinoma: The Role of Alpha-fetoprotein and Ultrasound with and without Ultrasound Contrast Agents. <i>Ultrasound</i> , 2005, 13, 219-225.	0.7	1
186	Enhancement by Estradiol 3-Benzoyate in Thioacetamide-Induced Liver Cirrhosis of Rats. <i>Toxicological Sciences</i> , 2005, 85, 720-726.	3.1	20
187	Staging classifications for hepatocellular carcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2005, 5, 377-383.	3.1	13
188	Contrast-Enhanced Sonography for the Characterisation of Hepatocellular Carcinomas - Correlation with Histological Differentiation. <i>Ultraschall in Der Medizin</i> , 2005, 26, 270-276.	1.5	66
189	Five-year Survival of Patients with Hepatocellular Carcinoma Treated with Laparoscopic Microwave Coagulation Therapy. <i>Endoscopy</i> , 2005, 37, 1220-1225.	1.8	31

#	ARTICLE	IF	CITATIONS
190	Functional CT Quantification of Tumor Perfusion after Transhepatic Arterial Embolization in a Rat Model. <i>Radiology</i> , 2005, 237, 144-150.	7.3	63
191	Single Nucleotide Polymorphisms Associated with Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection. <i>Intervirolgy</i> , 2005, 48, 10-15.	2.8	40
192	How to Predict HCC Development in Patients with Chronic B Viral Liver Disease?. <i>Intervirolgy</i> , 2005, 48, 23-28.	2.8	49
193	The role of T-fimbrin in the response to DNA damage: Silencing of T-fimbrin by small interfering RNA sensitizes human liver cancer cells to DNA-damaging agents. <i>International Journal of Oncology</i> , 2005, 27, 933.	3.3	5
194	243 Contrast-enhanced sonography in the characterization of small hepatocellular carcinomas in cirrhotic patients: Comparison with contrast-enhanced ultrafast magnetic resonance imaging. <i>Journal of Hepatology</i> , 2005, 42, 93-94.	3.7	38
195	Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 75-84.	4.4	77
196	Screening Tests for Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2005, 9, 235-251.	2.1	74
197	Alcohol in Hepatocellular Cancer. <i>Clinics in Liver Disease</i> , 2005, 9, 151-169.	2.1	67
198	The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2005, 42, 760-777.	3.7	180
199	A proteomics analysis of cellular proteins associated with HBV genotype-specific HBX: potential in identification of early diagnostic markers for HCC. <i>Journal of Clinical Virology</i> , 2005, 33, 293-298.	3.1	35
200	Attenuated phosphorylation of heat shock protein 27 correlates with tumor progression in patients with hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2005, 337, 337-342.	2.1	56
201	Comparison between the fifth and sixth editions of the AJCC/UICC TNM staging systems for hepatocellular carcinoma: multicentric study on 393 cirrhotic resected patients. <i>European Journal of Surgical Oncology</i> , 2005, 31, 760-767.	1.0	66
202	A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection. <i>Cancer Letters</i> , 2005, 229, 77-83.	7.2	35
203	Efficacy of Hepatocellular Carcinoma Locoregional Therapies on Patients Waiting for Liver Transplantation. <i>Transplantation Proceedings</i> , 2005, 37, 1484-1485.	0.6	10
204	Is transarterial chemoembolization necessary before liver transplantation for hepatocellular carcinoma?. <i>American Journal of Surgery</i> , 2005, 190, 383-387.	1.8	48
206	Automatic control of finite element models for temperature-controlled radiofrequency ablation. <i>BioMedical Engineering OnLine</i> , 2005, 4, 42.	2.7	44
207	Viral hepatitis and hepatocellular carcinoma. <i>World Journal of Surgical Oncology</i> , 2005, 3, 27.	1.9	125
208	Epidemiology of Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2005, 9, 191-211.	2.1	826

#	ARTICLE	IF	CITATIONS
209	Molecular Profiling of Hepatocellular Carcinoma in Mice with a Chronic Deficiency of Hepatic S-Adenosylmethionine: A Relevance in Human Liver Diseases. <i>Journal of Proteome Research</i> , 2006, 5, 944-953.	3.7	18
210	Effect of the Etiology of Viral Cirrhosis on the Survival of Patients with Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2006, 101, 91-98.	0.4	81
211	Comparison of Liver Biopsy and Noninvasive Methods for Diagnosis of Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 361-368.	4.4	60
213	Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. <i>Biological Chemistry</i> , 2006, 387, 349-60.	2.5	263
214	Molecular pathways in hepatocellular carcinoma. <i>Cancer Letters</i> , 2006, 240, 157-169.	7.2	86
215	Glutathione S-transferase M1 and T1 genetic polymorphisms are not related to the risk of hepatocellular carcinoma: A study in the Spanish population. <i>European Journal of Cancer</i> , 2006, 42, 73-77.	2.8	22
216	Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients. <i>Journal of Hepatology</i> , 2006, 44, S146-S150.	3.7	33
217	Molecular Pathogenesis of Hepatocellular Carcinoma. <i>Journal of Surgical Research</i> , 2006, 136, 125-135.	1.6	93
219	Chronic hepatitis B infection and liver cancer. <i>Biomedical Imaging and Intervention Journal</i> , 2006, 2, e7.	0.5	16
220	Liver targeting and the delayed drug release of the nanoparticles of adriamycin polybutylcyanoacrylate in mice. <i>Chinese Medical Journal</i> , 2006, 119, 1287-1293.	2.3	6
222	Liver Transplantation for Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 643-647.	2.2	14
223	Effect of a 188Re-SSS lipiodol/131I-lipiodol mixture, 188Re-SSS lipiodol alone or 131I-lipiodol alone on the survival of rats with hepatocellular carcinoma. <i>Nuclear Medicine Communications</i> , 2006, 27, 363-369.	1.1	11
224	Hepatocellular carcinoma. <i>Current Opinion in Gastroenterology</i> , 2006, 22, 248-253.	2.3	98
225	A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2006, 243, 321-328.	4.2	1,252
226	PIN1 expression contributes to hepatic carcinogenesis. <i>Journal of Pathology</i> , 2006, 210, 19-25.	4.5	53
227	Clinical features and prognosis of hepatocellular carcinoma in young patients from a hepatitis B-endemic area. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 588-594.	2.8	45
228	High dose vitamin K3 infusion in advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 060606032707036-???	2.8	15
229	Epidemiology, Risk Factors, and Natural History of Hepatocellular Carcinoma. <i>Annals of the New York Academy of Sciences</i> , 2002, 963, 13-20.	3.8	252

#	ARTICLE	IF	CITATIONS
230	Epidemiology of HBV infection and HBV-related hepatocellular carcinoma in Africa: natural history and clinical outcome. <i>ISBT Science Series</i> , 2006, 1, 84-88.	1.1	2
231	Expression of aspartyl beta-hydroxylase and its clinicopathological significance in hepatocellular carcinoma. <i>Modern Pathology</i> , 2006, 19, 280-286.	5.5	24
232	Viral hepatitis and liver cancer: the case of hepatitis C. <i>Oncogene</i> , 2006, 25, 3834-3847.	5.9	361
233	Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 792-800.	0.8	207
234	Outcome of 1000 Liver Cancer Patients Evaluated at the UPMC Liver Cancer Center. <i>Journal of Gastrointestinal Surgery</i> , 2006, 10, 63-68.	1.7	23
235	Detection of hepatocarcinoma in rats by integration of the fluorescence spectrum: Experimental model. <i>Laser Physics</i> , 2006, 16, 827-832.	1.2	5
236	A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2006, 41, 884-892.	5.1	81
237	Hepatocellular carcinoma " Rising incidence, changing therapeutic strategies. <i>Wiener Medizinische Wochenschrift</i> , 2006, 156, 404-409.	1.1	20
238	Evaluation of Important Treatment Parameters in Supraphysiological Thermal Therapy of Human Liver Cancer HepG2 Cells. <i>Annals of Biomedical Engineering</i> , 2006, 34, 1745-1757.	2.5	10
239	Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006, 132, 745-755.	2.5	52
240	N-Nitrosodiethylamine-Induced Pig Liver Hepatocellular Carcinoma Model: Radiological and Histopathological Studies. <i>CardioVascular and Interventional Radiology</i> , 2006, 29, 420-428.	2.0	39
241	Gene expression analysis of human hepatocellular carcinoma by using full-length cDNA library. <i>Journal of Biomedical Science</i> , 2006, 13, 241-249.	7.0	13
242	Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes. <i>Virology</i> , 2006, 349, 347-358.	2.4	72
243	Recovery from Liver Failure after Hepatectomy for Hepatocellular Carcinoma in Cirrhosis: Meaning of the Model for End-Stage Liver Disease. <i>Journal of the American College of Surgeons</i> , 2006, 203, 670-676.	0.5	51
244	Novel adenine adducts, N7-guanine-AFB1 adducts, and p53 mutations in patients with schistosomiasis and aflatoxin exposure. <i>Cancer Detection and Prevention</i> , 2006, 30, 491-498.	2.1	26
245	Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. <i>Cancer</i> , 2006, 107, 579-590.	4.1	99
246	A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-Butyl-2-Cyanoacrylate injection versus band ligation. <i>Hepatology</i> , 2006, 43, 690-697.	7.3	290
247	Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. <i>Hepatology</i> , 2006, 43, 891-902.	7.3	112

#	ARTICLE	IF	CITATIONS
248	Roles of reactive oxygen species in hepatocarcinogenesis and drug resistance gene expression in liver cancers. <i>Molecular Carcinogenesis</i> , 2006, 45, 701-709.	2.7	75
249	Cancer therapy: Back to metabolism. <i>Cancer Biology and Therapy</i> , 2006, 5, 986-987.	3.4	4
250	CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. <i>Cancer Biology and Therapy</i> , 2006, 5, 808-814.	3.4	95
251	Temporal and biological trends in liver cancers at a University hospital in Southwest Nigeria. <i>Tropical Doctor</i> , 2006, 36, 28-30.	0.5	5
252	Control of Differentiation in Progression of Epithelial Tumors. <i>Advances in Cancer Research</i> , 2006, 95, 61-113.	5.0	25
253	Suppression of Human Hepatoma Growth in vivo by a Monoclonal Antibody Against a Mr 45,000 Protein. <i>Cancer Investigation</i> , 2006, 24, 734-739.	1.3	0
254	The Molecular Diagnosis of Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2006, 43, 69-101.	6.1	12
255	Cooperative Interactions of p53 Mutation, Telomere Dysfunction, and Chronic Liver Damage in Hepatocellular Carcinoma Progression. <i>Cancer Research</i> , 2006, 66, 4766-4773.	0.9	114
256	Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. <i>British Journal of Cancer</i> , 2006, 95, 210-217.	6.4	152
257	A Homeobox Protein, Prox1, Is Involved in the Differentiation, Proliferation, and Prognosis in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 6005-6011.	7.0	89
258	Hepatitis B Virus Genotypes in Alaska Native People with Hepatocellular Carcinoma: Preponderance of Genotype F. <i>Journal of Infectious Diseases</i> , 2007, 195, 5-11.	4.0	246
259	Impact of Diabetes on Recurrence of Hepatocellular Carcinoma after Surgical Treatment in Patients With Viral Hepatitis. <i>American Journal of Gastroenterology</i> , 2007, 102, 1939-1946.	0.4	77
260	Association between aflatoxin exposure and health characteristics, liver function, hepatitis and malaria infections in Ghanaians. <i>Journal of Nutritional and Environmental Medicine</i> , 2007, 16, 242-257.	0.1	26
261	CpG Island Methylator Phenotype Association with Elevated Serum $\alpha$ -Fetoprotein Level in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 944-952.	7.0	60
262	Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: Helical CT and MR Imaging Findings with Clinical-Pathologic Comparison. <i>Radiology</i> , 2007, 243, 422-430.	7.3	70
263	Liver Resection or Combined Chemoembolization and Radiofrequency Ablation Improve Survival in Patients with Hepatocellular Carcinoma. <i>Digestion</i> , 2007, 75, 104-112.	2.3	52
264	Comparison of Percutaneous and Surgical Approaches for Radiofrequency Ablation of Small and Medium Hepatocellular Carcinoma. <i>Archives of Surgery</i> , 2007, 142, 1136.	2.2	53
265	Expression levels of heat shock protein 20 decrease in parallel with tumor progression in patients with hepatocellular carcinoma. <i>Oncology Reports</i> , 0, , .	2.6	7

#	ARTICLE	IF	CITATIONS
266	Modification of Acid-Base Balance in Cirrhotic Patients Undergoing Liver Resection for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2007, 245, 902-908.	4.2	16
267	Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma. <i>European Journal of Cancer Prevention</i> , 2007, 16, 196-202.	1.3	50
268	Mechanisms of anti-proliferative effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on human liver cancer cells. <i>Oncology Reports</i> , 2007, , .	2.6	4
269	Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinoma. <i>Human Pathology</i> , 2007, 38, 1508-1515.	2.0	45
270	Liver-directed therapies for hepatocellular cancer. <i>Community Oncology</i> , 2007, 4, 571-575.	0.2	1
271	Diffusion-Weighted Magnetic Resonance Imaging of Focal Hepatic Nodules in an Experimental Hepatocellular Carcinoma Rat Model. <i>Academic Radiology</i> , 2007, 14, 279-286.	2.5	30
273	Unexpected response to systemic chemotherapy in case of primarily nonresectable advanced disseminated intrahepatic cholangiocarcinoma. <i>World Journal of Surgical Oncology</i> , 2007, 5, 36.	1.9	13
274	Pin1 Interacts With a Specific Serine-Proline Motif of Hepatitis B Virus X-Protein to Enhance Hepatocarcinogenesis. <i>Gastroenterology</i> , 2007, 132, 1088-1103.	1.3	121
275	Intra-arterial Therapy of Liver Tumours. , 2007, , 491-508.		1
276	Management of Solitary 1â€‰cm to 2â€‰cm Liver Nodules in Patients with Compensated Cirrhosis: A Decision Analysis. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2007, 21, 491-500.	1.7	22
277	Subcellular Localization of APE1/Ref-1 in Human Hepatocellular Carcinoma: Possible Prognostic Significance. <i>Molecular Medicine</i> , 2007, 13, 89-96.	4.4	93
278	Biliary tract cancer and stones in relation to chronic liver conditions: A population-based study in Shanghai, China. <i>International Journal of Cancer</i> , 2007, 120, 1981-1985.	5.1	32
279	Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. <i>Hepatology</i> , 2007, 45, 42-52.	7.3	1,034
280	Long-acting octreotide versus placebo for treatment of advanced HCC: A randomized controlled double-blind study. <i>Hepatology</i> , 2007, 45, 9-15.	7.3	115
281	N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. <i>Hepatology</i> , 2007, 46, 1426-1435.	7.3	149
282	Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. <i>Hepatology</i> , 2008, 47, 511-520.	7.3	173
283	MDR1 gene polymorphisms and risk of recurrence in patients With hepatocellular carcinoma after liver transplantation. <i>Journal of Surgical Oncology</i> , 2007, 96, 62-68.	1.7	53
284	CD117 (c-kit) Expression in Human Hepatocellular Carcinoma. <i>Clinical Oncology</i> , 2007, 19, 204-208.	1.4	37



#	ARTICLE	IF	CITATIONS
285	Cimetidine inhibits epidermal growth factor-induced cell signaling. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 436-443.	2.8	15
286	Lower serum viral loads in young patients with hepatitis-B-virus-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007, 14, 153-160.	2.0	16
287	Toward the discovery of new biomarkers of hepatocellular carcinoma by proteomics. <i>Liver International</i> , 2007, 27, 163-173.	3.9	37
288	Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. <i>Liver International</i> , 2008, 28, 79-87.	3.9	105
289	Antitumor activity and mechanisms of action of total glycosides from aerial part of <i>Cimicifuga dahurica</i> targeted against hepatoma. <i>BMC Cancer</i> , 2007, 7, 237.	2.6	35
290	Survival and Recurrence Rates after Resection for Hepatocellular Carcinoma in Noncirrhotic Livers. <i>Journal of the American College of Surgeons</i> , 2007, 205, 27-36.	0.5	130
291	Viral Hepatitis and Hepatocellular Carcinoma. <i>Archives of Medical Research</i> , 2007, 38, 612-620.	3.3	49
292	Hepatocytes isolated from preneoplastic rat livers are resistant to ethacrynic acid cytotoxicity. <i>Archives of Toxicology</i> , 2007, 81, 565-573.	4.2	10
293	Causes of Death in Patients with Unresectable Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2007, 52, 3285-3289.	2.3	49
294	A meta-analysis of occupational trichloroethylene exposure and liver cancer. <i>International Archives of Occupational and Environmental Health</i> , 2007, 81, 127-143.	2.3	28
295	Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 825-834.	2.5	32
296	Radio Frequency Ablation for Hepatocellular Carcinoma in Cirrhotic Patients: Prognostic Factors for Survival. <i>Journal of Gastrointestinal Surgery</i> , 2007, 11, 143-149.	1.7	34
297	Hepatocellular carcinoma in viral hepatitis: Improving standard therapy. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2008, 22, 1137-1151.	2.4	20
298	Promotion of hepatocarcinogenesis in humans and animal models. <i>Archives of Toxicology</i> , 2008, 82, 623-631.	4.2	40
299	Malignant Liver Tumors in South African Children: A National Audit. <i>World Journal of Surgery</i> , 2008, 32, 1389-1395.	1.6	50
300	HA/GSAâ€Rmax Ratio as a Predictor of Postoperative Liver Failure. <i>World Journal of Surgery</i> , 2008, 32, 2410-2418.	1.6	26
301	Systemic therapy of hepatocellular carcinoma: Are we making progress?. <i>Advances in Therapy</i> , 2008, 25, 1089-1104.	2.9	79
302	Hepatocarcinoma: from pathogenic mechanisms to target therapy. <i>Oncology Reviews</i> , 2008, 2, 214-222.	1.8	2

#	ARTICLE	IF	CITATIONS
303	Is the prognosis of young patients with hepatocellular carcinoma poorer than the prognosis of older patients? A comparative analysis of clinical characteristics, prognostic features, and survival outcome. <i>Journal of Gastroenterology</i> , 2008, 43, 881-888.	5.1	56
304	APC promoter methylation and protein expression in hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 579-589.	2.5	47
305	Methylation-Related silencing of p14ARF gene correlates with telomerase activity and mRNA expression of human telomerase reverse transcriptase in hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2008, 98, 462-468.	1.7	14
306	Quantitative promoter methylation analysis of hepatocellular carcinoma, cirrhotic and normal liver. <i>International Journal of Cancer</i> , 2008, 122, 2800-2804.	5.1	52
307	Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma. <i>Hepatology</i> , 2008, 48, 1851-1863.	7.3	85
308	Biology of Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2008, 15, 962-971.	1.5	154
309	Incomplete Ablation After Radiofrequency Ablation of Hepatocellular Carcinoma: Analysis of Risk Factors and Prognostic Factors. <i>Annals of Surgical Oncology</i> , 2008, 15, 782-790.	1.5	73
310	Predictive Value of Expression and Promoter Hypermethylation of XAF1 in Hepatitis B Virus-Associated Hepatocellular Carcinoma Treated with Transplantation. <i>Annals of Surgical Oncology</i> , 2008, 15, 3494-3502.	1.5	22
311	Long-term outcome of hepatocellular carcinoma patients who underwent liver resection using microwave tissue coagulation. <i>Hpb</i> , 2008, 10, 289-295.	0.3	8
312	Age-related changes in albumin and actin of human myocardium. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2008, 2, 160-165.	0.4	0
313	Caffeine Inhibits the Proliferation of Liver Cancer Cells and Activates the MEK/ERK/EGFR Signalling Pathway. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008, 102, 543-551.	2.5	75
314	Tissue-specific transcription factors in progression of epithelial tumors. <i>Biochemistry (Moscow)</i> , 2008, 73, 573-591.	1.5	15
315	MMP2 promoter polymorphism (Câ€1306T) and risk of recurrence in patients with hepatocellular carcinoma after transplantation. <i>Clinical Genetics</i> , 2008, 73, 273-278.	2.0	29
316	Molecular background of Î±â€fetoprotein in liver cancer cells as revealed by global RNA expression analysis. <i>Cancer Science</i> , 2008, 99, 2402-2409.	3.9	30
317	Economic impact of extended treatment with peginterferon Î±-2a and ribavirin for slow hepatitis C virologic responders. <i>Journal of Viral Hepatitis</i> , 2008, 15, 293-299.	2.0	20
318	High expression of vanilloid receptor-1 is associated with better prognosis of patients with hepatocellular carcinoma. <i>Cancer Genetics and Cytogenetics</i> , 2008, 186, 25-32.	1.0	53
319	Risk Factors and Prognostic Factors of Local Recurrence after Radiofrequency Ablation of Hepatocellular Carcinoma. <i>Journal of the American College of Surgeons</i> , 2008, 207, 20-29.	0.5	172
320	Safety and Efficacy of Radiofrequency Ablation for Periductal Hepatocellular Carcinoma with Intraductal Cooling of the Central Bile Duct. <i>Journal of the American College of Surgeons</i> , 2008, 207, e1-e5.	0.5	14

#	ARTICLE	IF	CITATIONS
321	Risk factors of survival after percutaneous radiofrequency ablation of hepatocellular carcinoma. <i>Surgical Oncology</i> , 2008, 17, 23-31.	1.6	33
322	Locoregional Treatment of Malignant Hepatic Tumors with Biologic Response Modifiers. <i>Surgical Oncology Clinics of North America</i> , 2008, 17, 935-955.	1.5	2
323	Liver Cancer. , 2008, , 105-114.		2
324	Dramatic down-regulation of oxidoreductases in human hepatocellular carcinoma hepG2 cells: proteomics and gene ontology unveiling new frontiers in cancer enzymology. <i>Proteome Science</i> , 2008, 6, 29.	1.7	19
325	Significance of overexpression of alpha methylacyl-coenzyme A racemase in hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2008, 27, 2.	8.6	13
326	Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah <sup>-/-</sup> knockout mice model. <i>Journal of Hepatology</i> , 2008, 48, 308-317.	3.7	32
327	Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: Possibilities for prevention. <i>Mutation Research - Reviews in Mutation Research</i> , 2008, 659, 176-184.	5.5	122
328	Thoracoscopy-assisted magnetic resonance guided microwave coagulation therapy for hepatic tumors. <i>American Journal of Surgery</i> , 2008, 195, 854-860.	1.8	32
329	Hepatocellular carcinoma and the ubiquitin-proteasome system. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2008, 1782, 775-784.	3.8	39
330	Development of high-performance magnetic chemiluminescence enzyme immunoassay for $\alpha$ -fetoprotein (AFP) in human serum. <i>Clinica Chimica Acta</i> , 2008, 393, 90-94.	1.1	69
331	Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1739-1746.	2.8	44
332	High-dimensional biology to comprehend hepatocellular carcinoma. <i>Expert Review of Proteomics</i> , 2008, 5, 45-60.	3.0	23
333	An instrument to measure the convective heat transfer coefficient on large vessels. , 2008, 2008, 117-20.		0
334	Molecular Targeting in Hepatocellular Carcinoma. , 2008, , 165-210.		1
335	Altered $\beta$ -Catenin Accumulation in Hepatocellular Carcinomas of Diethylnitrosamine-Exposed Rhesus Macaques. <i>Toxicologic Pathology</i> , 2008, 36, 972-980.	1.8	5
336	Identification of Cystatin B as a Potential Serum Marker in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 1080-1089.	7.0	46
337	p19Arf Inhibits the Invasion of Hepatocellular Carcinoma Cells by Binding to C-terminal Binding Protein. <i>Cancer Research</i> , 2008, 68, 476-482.	0.9	56
338	Chemoembolization Combined with Pravastatin Improves Survival in Patients with Hepatocellular Carcinoma. <i>Digestion</i> , 2008, 78, 34-38.	2.3	94

#	ARTICLE	IF	CITATIONS
339	Association of MicroRNA Expression in Hepatocellular Carcinomas with Hepatitis Infection, Cirrhosis, and Patient Survival. <i>Clinical Cancer Research</i> , 2008, 14, 419-427.	7.0	486
340	Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1743-1749.	2.4	76
341	Squamous cell carcinoma antigen in human liver carcinogenesis. <i>Journal of Clinical Pathology</i> , 2008, 61, 445-447.	2.0	72
342	Cellular Retinaldehyde-Binding Protein-Like (CRALBPL), a Novel Human Sec14p-Like Gene That Is Upregulated in Human Hepatocellular Carcinomas, May Be Used as a Marker for Human Hepatocellular Carcinomas. <i>DNA and Cell Biology</i> , 2008, 27, 159-163.	1.9	11
343	Hepatocarcinoma in Viral and Metabolic Liver Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2008, 46, 370-375.	1.8	10
344	High-Throughput Protein-Based Technologies and Computational Models for Drug Development, Efficacy, and Toxicity. , 0, , 29-52.		4
345	Dosimetric evaluation and therapeutic response to internal radiation therapy of hepatocarcinomas using iodine-131-labelled lipiodol. <i>Nuclear Medicine Communications</i> , 2008, 29, 815-825.	1.1	24
346	Predictive Value of Liver Cell Dysplasia for Development of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 738-743.	2.2	30
347	Extracapsular Penetration is a New Prognostic Factor in Human Hepatocellular Carcinoma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1675-1682.	3.7	30
350	Proteomics of viruses. , 2008, , 309-343.		0
351	Detection of p53 codon 249 mutation in Nigerian patients with hepatocellular carcinoma using a novel evaluation of cell-free DNA. <i>Annals of Hepatology</i> , 2008, 7, 339-344.	1.5	22
352	Ultrasonography and computer tomography evaluation of hepatocellular carcinoma with cytohistopathological correlation. <i>Bangladesh Medical Research Council Bulletin</i> , 2008, 33, 73-77.	0.2	1
353	The Antitumor Effect and Hepatotoxicity of a Hexokinase II Inhibitor 3-Bromopyruvate: In Vivo Investigation of Intraarterial Administration in a Rabbit VX2 Hepatoma Model. <i>Korean Journal of Radiology</i> , 2009, 10, 596.	3.4	31
354	Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report. <i>Cases Journal</i> , 2009, 2, 18.	0.4	19
355	Imaging of liver cancer. <i>World Journal of Gastroenterology</i> , 2009, 15, 1289.	3.3	105
356	Percutaneous ethanol injection before liver transplantation in the hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2009, 8, 220-227.	1.5	16
357	The prolyl isomerase Pin1 interacts with a ribosomal protein S6 kinase to enhance insulin-induced AP-1 activity and cellular transformation. <i>Carcinogenesis</i> , 2009, 30, 671-681.	2.8	42
358	Clinical Profile, Etiology and Therapeutic Outcome in 324 Hepatocellular Carcinoma Patients at a Tertiary Care Center in India. <i>Oncology</i> , 2009, 77, 162-171.	1.9	51

#	ARTICLE	IF	CITATIONS
360	249 TP53 mutation has high prevalence and is correlated with larger and poorly differentiated HCC in Brazilian patients. <i>BMC Cancer</i> , 2009, 9, 204.	2.6	35
361	Twist expression promotes migration and invasion in hepatocellular carcinoma. <i>BMC Cancer</i> , 2009, 9, 240.	2.6	103
362	Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. <i>BMC Cancer</i> , 2009, 9, 389.	2.6	111
363	Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis. <i>Hepatology</i> , 2009, 49, 1962-1971.	7.3	100
364	Vascular endothelial growth factor in the management of hepatocellular carcinoma. <i>Cancer</i> , 2009, 115, 4895-4906.	4.1	106
365	The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes. <i>Journal of Surgical Oncology</i> , 2009, 99, 343-350.	1.7	47
366	Fascin expression in progression and prognosis of hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2009, 100, 575-579.	1.7	43
367	Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 1685-1692.	2.5	11
368	Reduction of anion exchanger 2 expression induces apoptosis of human hepatocellular carcinoma cells. <i>Molecular and Cellular Biochemistry</i> , 2009, 327, 135-144.	3.1	25
369	The Expression and Prognosis of FOXO3a and Skp2 in Human Hepatocellular Carcinoma. <i>Pathology and Oncology Research</i> , 2009, 15, 679-687.	1.9	56
370	Proton-Beam Therapy for Hepatocellular Carcinoma Associated with Portal Vein Tumor Thrombosis*. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 782-788.	2.0	109
371	Application of <sup>1</sup> H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. <i>Cancer Science</i> , 2009, 100, 782-785.	3.9	181
372	Expression of pro- and anti-inflammatory cytokines in relation to apoptotic genes in Egyptian liver disease patients associated with HCV genotype 4. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 416-428.	2.8	26
373	Hepatocellular carcinoma in the Asia pacific region. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 346-353.	2.8	407
374	Ultrasound-guided treatments under low acoustic power contrast harmonic imaging for hepatocellular carcinomas undetected by B-mode ultrasonography. <i>Liver International</i> , 2009, 29, 708-714.	3.9	59
375	A Prospective Study of Hypofractionated Proton Beam Therapy for Patients With Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 831-836.	0.8	196
376	Both Fibrous Capsule Formation and Extracapsular Penetration Are Powerful Predictors of Poor Survival in Human Hepatocellular Carcinoma: A Histological Assessment of 365 Patients in Japan. <i>Annals of Surgical Oncology</i> , 2009, 16, 2539-2546.	1.5	62
377	Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled study. <i>European Journal of Cancer</i> , 2009, 45, 1788-1797.	2.8	59

#	ARTICLE	IF	CITATIONS
378	Silencing of Hint1, a novel tumor suppressor gene, by promoter hypermethylation in hepatocellular carcinoma. <i>Cancer Letters</i> , 2009, 275, 277-284.	7.2	45
379	A snack enriched with oral branched-chain amino acids prevents a fall in albumin in patients with liver cirrhosis undergoing chemoembolization for hepatocellular carcinoma. <i>Nutrition Research</i> , 2009, 29, 89-93.	2.9	53
380	Risk factors and outcome of early recurrence after resection of small hepatocellular carcinomas. <i>American Journal of Surgery</i> , 2009, 198, 39-45.	1.8	43
381	Hepatic resection versus radiofrequency ablation for hepatocellular carcinoma in cirrhotic individuals not candidates for liver transplantation: A Markov model decision analysis. <i>American Journal of Surgery</i> , 2009, 198, 396-406.	1.8	72
382	Intracellular Innate Immune Cascades and Interferon Defenses That Control Hepatitis C Virus. <i>Journal of Interferon and Cytokine Research</i> , 2009, 29, 489-498.	1.2	87
383	Endoscopic thermal ablation therapies for hepatocellular carcinoma: a multi-center study. <i>Hepatology Research</i> , 2009, 39, 47-52.	3.4	27
384	Efficacy and Safety of Transarterial Chemoembolization in Recurrent Hepatocellular Carcinoma After Curative Surgical Resection. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 564-569.	1.3	32
385	Hepatobiliary Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 350-391.	4.9	719
386	Amperometric immunosensor for $\alpha$ -fetoprotein antigen in human serum based on co-immobilizing dinuclear copper complex and gold nanoparticle doped chitosan film. <i>Journal of Physics: Conference Series</i> , 2009, 188, 012047.	0.4	1
387	Therapeutics Based on microRNA: A New Approach for Liver Cancer. <i>Current Genomics</i> , 2010, 11, 311-325.	1.6	38
388	The cell cycle effects of docosahexaenoic acid on human metastatic hepatocellular carcinoma proliferation. <i>International Journal of Oncology</i> , 2010, 36, 991-8.	3.3	19
389	Pattern and Chronological Change of Iodized Oil Retention in Radiofrequency Ablation-Induced Vascular Injury Area. <i>Journal of Computer Assisted Tomography</i> , 2010, 34, 354-361.	0.9	1
390	Nonsurgical Options for Hepatocellular Carcinoma: Evolving Role of External Beam Radiotherapy. <i>Cancer Control</i> , 2010, 17, 100-110.	1.8	28
391	Knockdown of Thrombomodulin Enhances HCC Cell Migration through Increase of ZEB1 and Decrease of E-cadherin Gene Expression. <i>Annals of Surgical Oncology</i> , 2010, 17, 3379-3385.	1.5	25
392	Liver tumour segmentation using contrast-enhanced multi-detector CT data: performance benchmarking of three semiautomated methods. <i>European Radiology</i> , 2010, 20, 1738-1748.	4.5	38
393	Risk factors for postoperative recurrence of non- $\alpha$ non- $\beta$ hepatocellular carcinoma. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2010, 17, 291-295.	2.6	8
394	Stem Cell Therapy Improves the Outcome of Liver Resection in Cirrhotics. <i>Journal of Gastrointestinal Cancer</i> , 2010, 41, 17-23.	1.3	33
395	Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans. <i>Hepatology International</i> , 2010, 4, 523-529.	4.2	38

#	ARTICLE	IF	CITATIONS
396	Hepatitis B Vaccination Prevalence and its Predictors Among Asian, Pacific Islander, Native American, and Multiracial Adults in the National Health and Nutrition Examination Survey. <i>Journal of Immigrant and Minority Health</i> , 2010, 12, 847-852.	1.6	11
397	Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2010, 10, 317.	2.6	39
398	Î±-Bisabolol induces dose- and time-dependent apoptosis in HepG2 cells via a Fas- and mitochondrial-related pathway, involves p53 and NFÎ±B. <i>Biochemical Pharmacology</i> , 2010, 80, 247-254.	4.4	59
399	Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2010, 102, 462-468.	1.7	132
400	Investigation on supraphysiological thermal injury in two well-differentiated human hepatoma cell lines, HepG2 and Hep3B. <i>Journal of Thermal Biology</i> , 2010, 35, 411-416.	2.5	2
401	Hepatic progenitor cells in liver cancers from Asian children. <i>Liver International</i> , 2010, 30, 102-111.	3.9	21
402	Favorable Î±-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 605-612.	2.8	36
403	Liver transplantation for unresectable hepatocellular carcinoma in patients without liver cirrhosis. <i>Transplant International</i> , 2010, 23, 662-667.	1.6	27
404	Multimodal therapy for hepatocellular carcinoma: A complementary approach to liver transplantation. <i>Annals of Hepatology</i> , 2010, 9, 23-32.	1.5	12
405	The Role of Perfusion CT as a Follow-up Modality After Transcatheter Arterial Chemoembolization. <i>Investigative Radiology</i> , 2010, 45, 427-436.	6.2	55
406	Identification of Histone Deacetylase 3 as a Biomarker for Tumor Recurrence Following Liver Transplantation in HBV-Associated Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2010, 5, e14460.	2.5	101
407	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers. <i>Clinical Chemistry</i> , 2010, 56, e1-e48.	3.2	184
408	Transarterial embolisation of hepatocellular carcinoma with doxorubicin-eluting beads: single centre early experience. <i>Biomedical Imaging and Intervention Journal</i> , 2010, 6, e7.	0.5	16
409	Comparison of percutaneous 915 MHz microwave ablation and 2450 MHz microwave ablation in large hepatocellular carcinoma. <i>International Journal of Hyperthermia</i> , 2010, 26, 448-455.	2.5	56
410	Down-regulation of CYLD as a trigger for NF-Î±B activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells. <i>International Journal of Oncology</i> , 2010, 38, .	3.3	13
411	Comparison of Diffusion-Weighted with T2-weighted Imaging for Detection of Small Hepatocellular Carcinoma in Cirrhosis. <i>Academic Radiology</i> , 2010, 17, 239-243.	2.5	16
412	Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus-Related Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 192-199.	4.4	201
413	Longitudinal Quality of Life Assessment of Patients with Hepatocellular Carcinoma after Primary Transarterial Chemoembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 1024-1030.	0.5	41

#	ARTICLE	IF	CITATIONS
414	Fundamentals of Vascular Interventions. Learning Imaging, 2010, , 47-78.	0.0	0
415	Preventive effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on DEN-induced hepatocarcinogenesis in rats. Biomedicine and Pharmacotherapy, 2010, 64, 319-326.	5.6	11
416	Therapeutic effects and prognostic factors in high-intensity focused ultrasound combined with chemoembolisation for larger hepatocellular carcinoma. European Journal of Cancer, 2010, 46, 2513-2521.	2.8	47
417	Changes in tumor vascularity precede microbubble contrast accumulation deficit in the process of dedifferentiation of hepatocellular carcinoma. European Journal of Radiology, 2010, 75, e102-e106.	2.6	15
418	Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathologie Et Biologie, 2010, 58, 273-277.	2.2	233
419	Phenolic-Containing Organic Extracts of Mulberry ( <i>Morus alba</i> L.) Leaves Inhibit HepG2 Hepatoma Cells Through G2/M Phase Arrest, Induction of Apoptosis, and Inhibition of Topoisomerase II $\alpha$ Activity. Journal of Medicinal Food, 2010, 13, 1045-1056.	1.5	83
420	Chemokine CCL3 facilitates the migration of hepatoma cells by changing the concentration intracellular Ca <sup>2+</sup> . Hepatology Research, 2010, 40, 424-431.	3.4	10
421	New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma. Hepatology Research, 2010, 40, 1006-1014.	3.4	62
422	Compensatory enlargement of the liver after treatment of hepatocellular carcinoma with carbon ion radiotherapy – Relation to prognosis and liver function. Radiotherapy and Oncology, 2010, 96, 236-242.	0.6	30
423	Comparison of efficacy and toxicity of short-course carbon ion radiotherapy for hepatocellular carcinoma depending on their proximity to the porta hepatis. Radiotherapy and Oncology, 2010, 96, 231-235.	0.6	73
424	MWA Combined with TACE as a combined therapy for unresectable large-sized hepatocellular carcinoma. International Journal of Hyperthermia, 2011, 27, 654-662.	2.5	55
425	Surgical treatment of liver cancer: Experience of the A Coruña UHC (Spain). CirugÃa EspaÃ±ola (English) Tj ETQq1_1_0.784314 rgBT		
426	Hepatocellular Carcinoma: ., 2011, , .		4
428	Hepatitis B virus X protein stimulates the Hedgehog–Gli activation through protein stabilization and nuclear localization of Gli1 in liver cancer cells. Cancer Letters, 2011, 309, 176-184.	7.2	37
429	Hepatocellular carcinoma with portal vein tumor thrombosis: Improved treatment outcomes with external beam radiation therapy. Hepatology Research, 2011, 41, 813-824.	3.4	29
430	Could HBx Protein Expression Affect Signal Pathway Inhibition by Gefitinib or Selumetinib, a MEK Inhibitor, in Hepatocellular Carcinoma Cell Lines?. Journal of Korean Medical Science, 2011, 26, 214.	2.5	3
431	Radiofrequency ablation for recurrent hepatocellular carcinoma in postresectional patients. European Journal of Gastroenterology and Hepatology, 2011, 23, 1239-1244.	1.6	7
432	Potent antitumor actions of the new antibiotic boningmycin through induction of apoptosis and cellular senescence. Anti-Cancer Drugs, 2011, 22, 166-175.	1.4	12



#	ARTICLE	IF	CITATIONS
433	Autophagy inhibition enhances etoposide-induced cell death in human hepatoma G2 cells. <i>International Journal of Molecular Medicine</i> , 2011, 27, 599-606.	4.0	56
434	Risk of HBV Reactivation According to Viral Status and Treatment Intensity in Patients with Hepatocellular Carcinoma. <i>Antiviral Therapy</i> , 2011, 16, 969-977.	1.0	62
435	Evaluation of metabolic factors on the prognosis of patients undergoing resection of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 536-543.	2.8	17
436	Long term survival in patients with hepatocellular carcinoma directly invading the gastrointestinal tract: Case reports and literature review. <i>Surgical Oncology</i> , 2011, 20, e207-e214.	1.6	9
437	Chemoembolization agents for cancer treatment. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 44, 1-10.	4.0	61
439	Survival After Anatomic Resection Versus Nonanatomic Resection for Hepatocellular Carcinoma: A Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1626-1633.	2.3	63
440	Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study. <i>Investigational New Drugs</i> , 2011, 29, 1360-1369.	2.6	28
441	Clinical Presentation of Hepatocellular Carcinoma (HCC) in Asian-Americans Versus Non-Asian-Americans. <i>Journal of Immigrant and Minority Health</i> , 2011, 13, 842-848.	1.6	26
442	A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma. <i>Functional and Integrative Genomics</i> , 2011, 11, 419-429.	3.5	19
443	Current concepts in transarterial chemoembolization of hepatocellular carcinoma. <i>Abdominal Imaging</i> , 2011, 36, 677-683.	2.0	22
444	Potentiometric determination of $\beta$ -l-fucosidase enzyme by using 2-chloro-4-nitrophenol-rhodamine B ion pair chemical recognition in PVC membrane sensor. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 400, 787-795.	3.7	21
445	Quantitative measurement of human anti-HCV Core immunoglobulins on an electrical biochip platform. <i>Biosensors and Bioelectronics</i> , 2011, 26, 1895-1901.	10.1	11
446	Decreased expression of p39 is associated with a poor prognosis in human hepatocellular carcinoma. <i>Medical Oncology</i> , 2011, 28, 239-245.	2.5	12
447	Usefulness of Tc-99m-GSA scintigraphy for liver surgery. <i>Annals of Nuclear Medicine</i> , 2011, 25, 593-602.	2.2	32
448	Chemoprevention against hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2011, 4, 185-197.	0.8	14
449	Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2011, 11, 143.	2.0	69
450	Clinicopathologic and gene expression parameters predict liver cancer prognosis. <i>BMC Cancer</i> , 2011, 11, 481.	2.6	9
451	Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma. <i>World Journal of Surgical Oncology</i> , 2011, 9, 114.	1.9	46

#	ARTICLE	IF	CITATIONS
452	Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. <i>Journal of Translational Medicine</i> , 2011, 9, 171.	4.4	192
453	Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine?. <i>Cell and Bioscience</i> , 2011, 1, 5.	4.8	78
454	Treatment strategy for early hepatocellular carcinomas: Comparison of radiofrequency ablation with or without transcatheter arterial chemoembolization and surgical resection. <i>Journal of Surgical Oncology</i> , 2011, 104, 3-9.	1.7	24
455	A clustered ground-glass hepatocyte pattern represents a new prognostic marker for the recurrence of hepatocellular carcinoma after surgery. <i>Cancer</i> , 2011, 117, 2951-2960.	4.1	57
456	Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry. <i>Analytica Chimica Acta</i> , 2011, 691, 68-75.	5.4	98
457	Impact of different biochemical markers in serum of patients with benign and malignant liver diseases. <i>Journal of Advanced Research</i> , 2011, 2, 49-55.	9.5	4
458	Heterogeneous Type 4 Enhancement of Hepatocellular Carcinoma on Dynamic CT Is Associated With Tumor Recurrence After Radiofrequency Ablation. <i>American Journal of Roentgenology</i> , 2011, 197, W665-W673.	2.2	51
459	Previous Chemoembolization Response after Transcatheter Arterial Chemoembolization (TACE) Can Predict the Anti-Tumor Effect of Subsequent TACE with Miriplatin in Patients with Recurrent Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 80, 188-194.	1.9	17
460	Resveratrol interferes with N-nitrosodiethylamine-induced hepatocellular carcinoma at early and advanced stages in male Wistar rats. <i>Molecular Medicine Reports</i> , 2011, 4, 1211-7.	2.4	41
461	Interactions between hepatitis B virus and aflatoxin B1: effects on p53 induction in HepaRG cells. <i>Journal of General Virology</i> , 2012, 93, 640-650.	2.9	26
462	Transcatheter Arterial Chemotherapy Using Miriplatin-Lipiodol Suspension with or without Embolization for Unresectable Hepatocellular Carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 175-182.	1.3	15
463	Large-Scale Long-Term Follow-Up Study of Japanese Patients With Non-Alcoholic Fatty Liver Disease for the Onset of Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2012, 107, 253-261.	0.4	230
464	Pro-oncogenic potential of NM23-H2 in hepatocellular carcinoma. <i>Experimental and Molecular Medicine</i> , 2012, 44, 214.	7.7	27
465	The Effects of Anesthetic Technique on Cancer Recurrence in Percutaneous Radiofrequency Ablation of Small Hepatocellular Carcinoma. <i>Anesthesia and Analgesia</i> , 2012, 114, 290-296.	2.2	82
466	TLR3 dsRNA agonist inhibits growth and invasion of HepG2.2.15 HCC cells. <i>Oncology Reports</i> , 2012, 28, 200-6.	2.6	17
467	Radiofrequency ablation combined with transcatheter arterial embolisation in rabbit liver: investigation of the ablation zone according to the time interval between the two therapies. <i>British Journal of Radiology</i> , 2012, 85, e987-e994.	2.2	20
468	Preventive effect of caffeine and curcumin on hepatocellular carcinoma carcinogenesis in diethylnitrosamine-induced rats. <i>International Journal of Oncology</i> , 2012, 40, 1779-88.	3.3	8
469	Multidetector Computed Tomography Triphasic Evaluation of the Liver Before Transplantation. <i>Journal of Computer Assisted Tomography</i> , 2012, 36, 213-219.	0.9	15

#	ARTICLE	IF	CITATIONS
470	What is the role of radiation therapy in treating liver tumors?. <i>Clinical Practice (London, England)</i> , 2012, 9, 683-699.	0.1	0
471	Diabetes Worsens the Surgical Outcomes in Cirrhotic Patients with Hepatocellular Carcinoma. <i>Tohoku Journal of Experimental Medicine</i> , 2012, 227, 73-81.	1.2	25
472	Sorafenib in liver cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1059-1067.	1.8	50
473	Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. <i>Hepatology</i> , 2012, 56, 1817-1827.	7.3	136
474	Combination of flavopiridol and embelin effectively inhibit cell growth in hepatocellular carcinoma depending on regulatory relationship between CDK6 and XIAP. <i>Medicinal Chemistry Research</i> , 2012, 21, 3369-3375.	2.4	2
475	The Monoclonal Antibody CH12 Enhances the Sorafenib-Mediated Growth Inhibition of Hepatocellular Carcinoma Xenografts Expressing Epidermal Growth Factor Receptor Variant III. <i>Neoplasia</i> , 2012, 14, 509-518.	5.3	20
476	Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre. <i>Hpb</i> , 2012, 14, 162-170.	0.3	11
477	Clinicopathologic characteristics of patients with non-B non-C hepatitis virus hepatocellular carcinoma after hepatectomy. <i>American Journal of Surgery</i> , 2012, 204, 300-307.	1.8	34
478	Liver transplantation for unresectable hepatocellular carcinoma in normal livers. <i>Journal of Hepatology</i> , 2012, 57, 297-305.	3.7	49
479	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. <i>Journal of Hepatology</i> , 2012, 57, 821-829.	3.7	736
480	Chemoprevention of liver cancer by plant polyphenols. <i>Food and Chemical Toxicology</i> , 2012, 50, 2155-2170.	3.6	153
481	Quantitative dual energy CT measurements in rabbit VX2 liver tumors: Comparison to perfusion CT measurements and histopathological findings. <i>European Journal of Radiology</i> , 2012, 81, 1766-1775.	2.6	35
482	Genetic signatures shared in embryonic liver development and liver cancer define prognostically relevant subgroups in HCC. <i>Molecular Cancer</i> , 2012, 11, 55.	19.2	30
483	Persistent increase in alpha-fetoprotein level in a patient without underlying liver disease who underwent curative resection of hepatocellular carcinoma. A case report and review of the literature. <i>World Journal of Surgical Oncology</i> , 2012, 10, 79.	1.9	13
484	Chemotherapeutic efficacy of limonin against Aflatoxin B1 induced primary hepatocarcinogenesis in Wistar albino rats. <i>Biomedicine and Aging Pathology</i> , 2012, 2, 206-211.	0.8	12
485	Laparoscopic vs. open liver resection for malignant liver disease. A systematic review. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2012, 10, 194-201.	1.8	42
486	Role of glypican-3 in the early diagnosis of hepatocellular carcinoma among Egyptian patients. <i>Journal of Genetic Engineering and Biotechnology</i> , 2012, 10, 73-79.	3.3	8
487	Lipocalin-2 Induces Apoptosis in Human Hepatocellular Carcinoma Cells Through Activation of Mitochondria Pathways. <i>Cell Biochemistry and Biophysics</i> , 2012, 64, 177-186.	1.8	24

#	ARTICLE	IF	CITATIONS
488	Decreased expression of ALDH1L1 is associated with a poor prognosis in hepatocellular carcinoma. <i>Medical Oncology</i> , 2012, 29, 1843-1849.	2.5	32
489	MAGE-4 gene m-RNA and TGF in blood as potential biochemical markers for HCC in HCV-infected patients. <i>Medical Oncology</i> , 2012, 29, 3055-3062.	2.5	4
490	Are autologous bone marrow stem cell transplantation and transcatheter arterial embolization the best choices for patients with hepatocellular carcinoma and hepatic dysfunction? Report of a case. <i>Surgery Today</i> , 2012, 42, 1225-1228.	1.5	1
491	Immunoassay for serum alpha-fetoprotein using silver nanoparticles and detection via resonance light scattering. <i>Mikrochimica Acta</i> , 2012, 179, 241-248.	5.0	14
493	Disease-Free Survival after Hepatic Resection in Hepatocellular Carcinoma Patients: A Prediction Approach Using Artificial Neural Network. <i>PLoS ONE</i> , 2012, 7, e29179.	2.5	60
494	ShRNA-Targeted COMMD7 Suppresses Hepatocellular Carcinoma Growth. <i>PLoS ONE</i> , 2012, 7, e45412.	2.5	24
495	Sequential analysis of diethylnitrosamine-induced hepatocarcinogenesis in rats. <i>Experimental and Therapeutic Medicine</i> , 2012, 3, 371-378.	1.8	14
496	Promising Urinary Protein Biomarkers for the Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients. <i>Journal of Cancer</i> , 2012, 3, 390-403.	2.5	25
497	Impact social et psychologique des jeux d'argent en ligne chez les jeunes adultes. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2012, 196, 27-36.	0.0	5
498	Blockade of the sonic hedgehog pathway effectively inhibits the growth of hepatoma in mice: An in vivo study. <i>Oncology Letters</i> , 2012, 4, 1158-1162.	1.8	23
499	Hemoperitoneo secundario a rotura de carcinoma hepatocelular: Hallazgos de autopsia. <i>Cuadernos De Medicina Forense</i> , 2012, 18, 39-42.	0.0	0
500	BC047440 antisense eukaryotic expression vectors inhibited HepG2 cell proliferation and suppressed xenograft tumorigenicity. <i>Brazilian Journal of Medical and Biological Research</i> , 2012, 45, 97-103.	1.5	1
501	Bif-1 is overexpressed in hepatocellular carcinoma and correlates with shortened patient survival. <i>Oncology Letters</i> , 2012, 3, 851-854.	1.8	7
502	Serum and glucocorticoid kinase 3 at 8q13.1 promotes cell proliferation and survival in hepatocellular carcinoma. <i>Hepatology</i> , 2012, 55, 1754-1765.	7.3	41
503	A Prospective Randomized Controlled Trial of Preoperative Whole-Liver Chemolipiodolization for Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1404-1412.	2.3	31
504	Clinical prognostic variables in young patients (under 40 years) with hepatitis B virus-associated hepatocellular carcinoma. <i>Journal of Digestive Diseases</i> , 2012, 13, 214-218.	1.5	11
505	Cost-effectiveness analysis on the surveillance for hepatocellular carcinoma in liver cirrhosis patients using contrast-enhanced ultrasonography. <i>Hepatology Research</i> , 2012, 42, 376-384.	3.4	51
506	Late-evening snack with branched-chain amino acids improves liver function after radiofrequency ablation for hepatocellular carcinoma. <i>Hepatology Research</i> , 2012, 42, 658-667.	3.4	34

#	ARTICLE	IF	CITATIONS
507	Proteomic analysis of human hepatoma cells expressing methionine adenosyltransferase I/III. <i>Journal of Proteomics</i> , 2012, 75, 2855-2868.	2.4	11
508	Polysaccharides from <i>Phellinus linteus</i> inhibit cell growth and invasion and induce apoptosis in HepG2 human hepatocellular carcinoma cells. <i>Biologia (Poland)</i> , 2012, 67, 247-254.	1.5	17
509	FBI $\alpha$ 1 promotes cell proliferation and enhances resistance to chemotherapy of hepatocellular carcinoma in vitro and in vivo. <i>Cancer</i> , 2012, 118, 134-146.	4.1	35
510	Distinct DNA methylation patterns in cirrhotic liver and hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2012, 130, 1319-1328.	5.1	80
511	Chemotherapy with PLGA microspheres containing docetaxel decreases angiogenesis in human hepatoma xenograft. <i>Medical Oncology</i> , 2012, 29, 62-69.	2.5	7
512	The role and mechanisms of nanoparticles to enhance radiosensitivity in hepatocellular cell. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 569-575.	5.6	52
513	Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes. <i>Journal of Gastroenterology</i> , 2013, 48, 951-965.	5.1	37
514	Surgical Resection versus Open-Approach Radiofrequency Ablation for Small Hepatocellular Carcinomas within Milan Criteria after Successful Transcatheter Arterial Chemoembolization. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 1752-1759.	1.7	10
515	Imaging of hepatocellular carcinoma recurrence post liver resection: A pictorial essay. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2013, 57, 337-344.	1.8	0
516	Clinicopathological Features of Recurrence in Patients After 10-year Disease-free Survival Following Curative Hepatic Resection of Hepatocellular Carcinoma. <i>World Journal of Surgery</i> , 2013, 37, 820-828.	1.6	19
517	Perioperative exercise for chronic liver injury patients with hepatocellular carcinoma undergoing hepatectomy. <i>American Journal of Surgery</i> , 2013, 206, 202-209.	1.8	87
518	Evaluation of serum nitric oxide before and after local radiofrequency thermal ablation for hepatocellular carcinoma. <i>Alexandria Journal of Medicine</i> , 2013, 49, 67-73.	0.6	3
520	Anticancer potential of rhamnocitrin 4 $\beta$ -D-galactopyranoside against N-diethylnitrosamine-induced hepatocellular carcinoma in rats. <i>Molecular and Cellular Biochemistry</i> , 2013, 384, 147-153.	3.1	17
521	Assessment of preoperative exercise capacity in hepatocellular carcinoma patients with chronic liver injury undergoing hepatectomy. <i>BMC Gastroenterology</i> , 2013, 13, 119.	2.0	21
522	Tackling hepatitis B virus-associated hepatocellular carcinoma—the future is now. <i>Cancer and Metastasis Reviews</i> , 2013, 32, 229-268.	5.9	19
523	Long-term outcomes after curative resection for patients with macroscopically solitary hepatocellular carcinoma without macrovascular invasion and an analysis of prognostic factors. <i>Medical Oncology</i> , 2013, 30, 696.	2.5	21
524	Hepatitis B vaccines. , 2013, , 205-234.		13
525	Early diffuse recurrence of hepatocellular carcinoma after percutaneous radiofrequency ablation: analysis of risk factors. <i>European Radiology</i> , 2013, 23, 190-197.	4.5	67

#	ARTICLE	IF	CITATIONS
526	Transarterial chemoembolization for the treatment of hepatocellular carcinoma: A single center experience including 221 patients. <i>Journal of the Egyptian National Cancer Institute</i> , 2013, 25, 143-150.	1.5	12
527	Impact of PIVKA-II in diagnosis of hepatocellular carcinoma. <i>Journal of Advanced Research</i> , 2013, 4, 539-546.	9.5	27
528	How bioinformatics influences health informatics: usage of biomolecular sequences, expression profiles and automated microscopic image analyses for clinical needs and public health. <i>Health Information Science and Systems</i> , 2013, 1, 2.	5.2	32
529	A Prospective Randomized Controlled Trial to Compare Pringle Manoeuvre with Hemi-hepatic Vascular Inflow Occlusion in Liver Resection for Hepatocellular Carcinoma with Cirrhosis. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 1414-1421.	1.7	24
530	Effectiveness and safety of doxorubicin loaded beads in hepatocellular carcinoma. <i>International Journal of Clinical Pharmacy</i> , 2013, 35, 1105-1112.	2.1	2
531	Identification of biomarkers for hepatocellular carcinoma using network-based bioinformatics methods. <i>European Journal of Medical Research</i> , 2013, 18, 35.	2.2	11
532	Effects of umbelliferone on lipid peroxidation and antioxidant status in diethylnitrosamine-induced hepatocellular carcinoma. <i>Journal of Acute Medicine</i> , 2013, 3, 73-82.	0.2	24
533	A Taiwanese Propolis Derivative Induces Apoptosis through Inducing Endoplasmic Reticular Stress and Activating Transcription Factor-3 in Human Hepatoma Cells. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-11.	1.2	5
534	Intra-atrial tumour thrombus secondary to hepatocellular carcinoma. <i>Australasian Medical Journal</i> , 2013, 6, 321-324.	0.1	10
535	A Spotlight on Chemical Constituents and Pharmacological Activities of <i>Nigella glandulifera</i> Freyn et Sint Seeds. <i>Journal of Chemistry</i> , 2013, 2013, 1-12.	1.9	33
536	A dose-volume intercomparison of volumetric-modulated arc therapy, 3D static conformal, and rotational conformal techniques for portal vein tumor thrombus in hepatocellular carcinoma. <i>Journal of Radiation Research</i> , 2013, 54, 697-705.	1.6	1
537	Minimum resection margin should be based on tumor size in hepatectomy for hepatocellular carcinoma in hepatoviral infection patients. <i>Hepatology Research</i> , 2013, 43, 1295-1303.	3.4	32
538	Radiation dose dependent risk of liver cancer mortality in the German uranium miners cohort 1946-2003. <i>Journal of Radiological Protection</i> , 2013, 33, 175-185.	1.1	7
539	Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system. <i>Hpb</i> , 2013, 15, 439-448.	0.3	81
540	Human hepatocyte carcinogenesis. <i>International Journal of Oncology</i> , 2013, 42, 1133-1138.	3.3	105
541	The Effect of Long-term Supplementation With Branched-chain Amino Acid Granules in Patients With Hepatitis C Virus-related Hepatocellular Carcinoma After Radiofrequency Thermal Ablation. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 359-366.	2.2	36
542	Feasibility of Sorafenib Combined with Local Radiotherapy in Advanced Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2013, 54, 1178.	2.2	27
543	Hepatobiliary Diseases. , 2013, , 28-34.		0

#	ARTICLE	IF	CITATIONS
544	Hepatic Resection for Hepatocellular Carcinoma in the Elderly. <i>Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)</i> , 2013, 38, 224-231.	0.0	1
545	Cellular basis of hepatic fibrosis and its role in inflammation and cancer. <i>Frontiers in Bioscience - Scholar</i> , 2013, S5, 217-230.	2.1	89
546	Epidemiology and Prevention of Viral Hepatitis B and C. , 0, , .		1
547	Hepatocellular Carcinoma, Steroid Hormones and Metalloproteases. , 0, , .		0
548	Hepatocellular carcinoma: epidemiology and risk factors. <i>Journal of Hepatocellular Carcinoma</i> , 2014, 1, 115.	3.7	88
549	Spatial Analysis of the Home Addresses of Hospital Patients with Hepatitis B Infection or Hepatoma in Shenzhen, China from 2010 to 2012. <i>International Journal of Environmental Research and Public Health</i> , 2014, 11, 3143-3155.	2.6	10
550	Anticancer and apoptosis-inducing effects of <i>Moringa concanensis</i> using hepG2 cell lines. <i>Bangladesh Journal of Pharmacology</i> , 2014, 9, .	0.4	12
551	A comparison between surgical resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. <i>Annals of Surgical Treatment and Research</i> , 2014, 87, 72.	1.0	38
552	Using proteomics to identify the HBx interactome in hepatitis B virus: how can this inform the clinic?. <i>Expert Review of Proteomics</i> , 2014, 11, 59-74.	3.0	18
553	Increased expression of annexin A1 predicts poor prognosis in human hepatocellular carcinoma and enhances cell malignant phenotype. <i>Medical Oncology</i> , 2014, 31, 327.	2.5	41
554	Highâ€spatial and highâ€temporal resolution dynamic contrastâ€enhanced perfusion imaging of the liver with timeâ€resolved threeâ€dimensional radial MRI. <i>Magnetic Resonance in Medicine</i> , 2014, 71, 934-941.	3.0	29
555	Syntheses and anti-cancer activities of derivatives of tetrandrine and fangchinoline. <i>Chemical Research in Chinese Universities</i> , 2014, 30, 937-940.	2.6	13
556	Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome. <i>ISRN Hepatology</i> , 2014, 2014, 1-25.	0.9	18
557	Promoter Methylation of<i>SFRP3</i>Is Frequent in Hepatocellular Carcinoma. <i>Disease Markers</i> , 2014, 2014, 1-10.	1.3	18
558	Synergistic effect of celecoxib in tumor necrosis factor-related apoptosis-inducing ligand treatment in osteosarcoma cells. <i>Molecular Medicine Reports</i> , 2014, 10, 2198-2202.	2.4	5
559	Fuzzy expert system for the risk identification of the hepatocellular carcinoma. , 2014, , .		0
560	Advances in non-surgical management of primary liver cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 16630.	3.3	53
561	Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma. <i>Journal of Translational Medicine</i> , 2014, 12, 273.	4.4	52

#	ARTICLE	IF	CITATIONS
562	Null anticarcinogenic effect of silymarin on diethylnitrosamine-induced hepatocarcinogenesis in rats. <i>Experimental and Therapeutic Medicine</i> , 2014, 7, 31-38.	1.8	19
563	The Incidental Finding of Hepatocellular Carcinoma by Echocardiography. <i>Journal of Diagnostic Medical Sonography</i> , 2014, 30, 328-331.	0.3	0
564	Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: A RCT. <i>Journal of Hepatology</i> , 2014, 61, 82-88.	3.7	271
565	A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. <i>Journal of Clinical Immunology</i> , 2014, 34, 194-203.	3.8	73
566	Characterization of a novel PXR isoform with potential dominant-negative properties. <i>Journal of Hepatology</i> , 2014, 61, 609-616.	3.7	15
567	Evaluation of serum PIVKA-II and MIF as diagnostic markers for HCV/HBV induced hepatocellular carcinoma. <i>Microbial Pathogenesis</i> , 2014, 77, 31-35.	2.9	7
568	Global PROTOMAP Profiling to Search for Biomarkers of Early-Recurrent Hepatocellular Carcinoma. <i>Journal of Proteome Research</i> , 2014, 13, 4847-4858.	3.7	23
569	Role of ZIC1 methylation in hepatocellular carcinoma and its clinical significance. <i>Tumor Biology</i> , 2014, 35, 7429-7433.	1.8	18
570	The expression of beclin-1, an autophagic gene, in hepatocellular carcinoma associated with clinical pathological and prognostic significance. <i>BMC Cancer</i> , 2014, 14, 327.	2.6	97
571	Tamoxifen compared to best supportive care in advanced hepatocellular carcinoma: A retrospective matched-cohort study. <i>Journal of the Egyptian National Cancer Institute</i> , 2014, 26, 1-7.	1.5	1
572	Characteristics of combined hepatocellular-cholangiocarcinoma and comparison with intrahepatic cholangiocarcinoma. <i>European Journal of Surgical Oncology</i> , 2014, 40, 976-981.	1.0	53
574	Identification of copy number variation-driven genes for liver cancer via bioinformatics analysis. <i>Oncology Reports</i> , 2014, 32, 1845-1852.	2.6	14
575	Latexin exhibits tumor suppressor potential in hepatocellular carcinoma. <i>Oncology Reports</i> , 2014, 31, 1364-1372.	2.6	17
576	TGF- $\beta$ 2/Smad signaling during hepatic fibro-carcinogenesis (Review). <i>International Journal of Oncology</i> , 2014, 45, 1363-1371.	3.3	109
577	Solamargine triggers hepatoma cell death through apoptosis. <i>Oncology Letters</i> , 2015, 10, 168-174.	1.8	30
579	Aberrantly regulated dysadherin and B-cell lymphoma 2/B-cell lymphoma 2-associated X enhances tumorigenesis and DNA targeting drug resistance of liver cancer stem cells. <i>Molecular Medicine Reports</i> , 2015, 12, 7239-7246.	2.4	10
580	Effects of coenzyme Q10 supplementation on antioxidant capacity and inflammation in hepatocellular carcinoma patients after surgery: a randomized, placebo-controlled trial. <i>Nutrition Journal</i> , 2015, 15, 85.	3.4	59
581	Preparation of carbon-coated iron nanofluid and its application in radiofrequency ablation. , 2015, 103, 908-914.		10



#	ARTICLE	IF	CITATIONS
582	AROS Is a Significant Biomarker for Tumor Aggressiveness in Non-cirrhotic Hepatocellular Carcinoma. <i>Journal of Korean Medical Science</i> , 2015, 30, 1253.	2.5	7
583	Problems of Long Survival Following Surgery in Patients with NonBNonC-HCC: Comparison with HBV and HCV Related-HCC. <i>Journal of Cancer</i> , 2015, 6, 438-447.	2.5	17
585	Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics. <i>Frontiers in Immunology</i> , 2015, 6, 424.	4.8	12
586	Untreated hepatocellular carcinoma in Egypt: outcome and prognostic factors. <i>Journal of Hepatocellular Carcinoma</i> , 2015, 2, 3.	3.7	18
587	Effect of Intramuscular Adipose Tissue Content on Prognosis in Patients Undergoing Hepatocellular Carcinoma Resection. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 1315-1323.	1.7	45
588	Intra-arterial chemoembolization with hepasphere 50â€“100Î¼m for patients with unresectable hepatocellular carcinoma: Initial experience in Egyptian Liver Hospital. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2015, 46, 957-965.	0.6	0
589	Glycosylation and Liver Cancer. <i>Advances in Cancer Research</i> , 2015, 126, 257-279.	5.0	128
590	Sonic hedgehog pathway inhibitor mitigates mouse hepatocellular carcinoma. <i>American Journal of Surgery</i> , 2015, 210, 554-560.	1.8	17
591	Surgical Resection and Liver Transplantation for Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2015, 19, 381-399.	2.1	78
592	A polysaccharide from mushroom Huaier retards human hepatocellular carcinoma growth, angiogenesis, and metastasis in nude mice. <i>Tumor Biology</i> , 2015, 36, 2929-2936.	1.8	38
593	Optical diagnosis of the progression and reversal of CCl <sub>4</sub> -induced liver injury in rodent model using minimally invasive autofluorescence spectroscopy. <i>Analyst, The</i> , 2015, 140, 3773-3780.	3.5	17
594	Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway. <i>BMC Cancer</i> , 2015, 15, 542.	2.6	58
595	Incidence and risk factors of hepatocellular carcinoma in patients with hepatic venous outflow tract obstruction. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 961-971.	3.7	40
596	Prognostic Factors and Clinical Characteristics for Hepatocellular Carcinoma Patients with Benign Enlarged Perihepatic Lymph Nodes: a Single-Center Experience from China. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 1822-1832.	1.7	3
597	Activation of Slit2-Robo1 signaling promotes liver fibrosis. <i>Journal of Hepatology</i> , 2015, 63, 1413-1420.	3.7	69
598	Relationship between polymorphism of angiotensin-converting enzyme gene insertion/deletion and risk of hepatocellular carcinoma in a Chinese Dai population. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015, 16, 695-699.	1.7	16
599	Influence of Rictor and Raptor Expression of mTOR Signaling on Long-Term Outcomes of Patients with Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2015, 60, 919-928.	2.3	28
600	The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China : role of chronic hepatitis B virus infection and aflatoxin B1 exposure. <i>Liver International</i> , 2015, 35, 999-1009.	3.9	69

#	ARTICLE	IF	CITATIONS
601	Y90 Selective Internal Radiation Therapy. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 167-185.	1.5	14
602	Nuclear shuttling of Y Box binding protein-1, its clinical relevance in cancer and as a therapeutic target. <i>Bangladesh Journal of Pharmacology</i> , 2016, 11, 501.	0.4	5
604	Association between Aflatoxin M1 and Liver Disease in HBV/HCV Infected Persons in Ghana. <i>International Journal of Environmental Research and Public Health</i> , 2016, 13, 377.	2.6	40
605	Chalcone-Induced Apoptosis through Caspase-Dependent Intrinsic Pathways in Human Hepatocellular Carcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2016, 17, 260.	4.1	30
606	Incidence and mortality of liver cancer and their relationship with the human development index in the world. <i>Biomedical Research and Therapy</i> , 2016, 3, .	0.6	7
607	Sex-specific associations between birth weight and adult primary liver cancer in a large cohort of Danish children. <i>International Journal of Cancer</i> , 2016, 138, 1410-1415.	5.1	14
608	Liver Stiffness and Serum Alpha-Fetoprotein in Discriminating Small Hepatocellular Carcinoma from Cirrhotic Nodule. <i>Ultrasound Quarterly</i> , 2016, 32, 319-326.	0.8	3
609	Hepatic resection versus transarterial chemoembolization for patients with Barcelona Clinic Liver Cancer intermediate stage Child-Pugh A hepatocellular carcinoma. <i>Experimental and Therapeutic Medicine</i> , 2016, 12, 3813-3819.	1.8	20
610	MicroRNA-497 regulates cell proliferation in hepatocellular carcinoma. <i>Oncology Letters</i> , 2016, 11, 1081-1088.	1.8	13
611	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shuangbai San for Treating Primary Liver Cancer Patients With Cancer Pain. <i>Journal of Pain and Symptom Management</i> , 2016, 51, 979-986.	1.2	17
612	Visualization of microvasculature and thrombi by X-ray phase-contrast computed tomography in hepatocellular carcinoma. <i>Journal of Synchrotron Radiation</i> , 2016, 23, 600-605.	2.4	12
613	Quantitative proteome analysis reveals the correlation between endocytosis-associated proteins and hepatocellular carcinoma dedifferentiation. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2016, 1864, 1579-1585.	2.3	19
614	TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials. <i>British Journal of Cancer</i> , 2016, 115, 1201-1205.	6.4	19
615	Gemcitabine and Antisense-microRNA Co-encapsulated PLGA-PEG Polymer Nanoparticles for Hepatocellular Carcinoma Therapy. <i>ACS Applied Materials &amp; Interfaces</i> , 2016, 8, 33412-33422.	8.0	74
616	Environmental Carcinogens and Risk for Human Liver Cancer. , 2016, , 25-41.		0
617	Mueller matrix microscope: a quantitative tool to facilitate detections and fibrosis scorings of liver cirrhosis and cancer tissues. <i>Journal of Biomedical Optics</i> , 2016, 21, 071112.	2.6	121
618	Ras-association domain family 10 acts as a novel tumor suppressor through modulating MMP2 in hepatocarcinoma. <i>Oncogenesis</i> , 2016, 5, e237-e237.	4.9	18
619	Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in the treatment of advanced hepatocellular carcinoma. <i>Oncology Letters</i> , 2016, 12, 707-714.	1.8	11

#	ARTICLE	IF	CITATIONS
620	Effect of several PEO-PPG amphiphiles on <i>bax</i> , <i>bcl-2</i> , and <i>hTERT</i> mRNAs: An insight into apoptosis and cell immortalization induced in hepatoma cells by these polymeric excipients. <i>Biotechnology and Applied Biochemistry</i> , 2016, 63, 273-280.	3.1	4
621	Visual detection of serum asialohaptoglobin by plasmonic sandwich ELLSA – a new platform for cirrhosis diagnosis. <i>Analyst, The</i> , 2016, 141, 76-84.	3.5	12
622	Anti-proliferative and apoptosis-triggering potential of disulfiram and disulfiram-loaded polysorbate 80-stabilized PLGA nanoparticles on hepatocellular carcinoma Hep3B cell line. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 1641-1650.	3.3	27
623	Rates of Treatment Eligibility in Follow-Up of Patients with Chronic Hepatitis B (CHB) Across Various Clinical Settings Who Were Initially Ineligible at Presentation. <i>Digestive Diseases and Sciences</i> , 2016, 61, 618-625.	2.3	14
624	Hepatitis viruses exploitation of host DNA methyltransferases functions. <i>Clinical and Experimental Medicine</i> , 2016, 16, 265-272.	3.6	8
625	The ubiquitin-proteasome system and its potential application in hepatocellular carcinoma therapy. <i>Cancer Letters</i> , 2016, 379, 245-252.	7.2	62
626	Effects of implementing an enhanced recovery after surgery program on patients undergoing resection of hepatocellular carcinoma. <i>Surgery Today</i> , 2017, 47, 42-51.	1.5	31
627	Studies of anticancer drug cytotoxicity based on long-term HepG2 spheroid culture in a microfluidic system. <i>Electrophoresis</i> , 2017, 38, 1206-1216.	2.4	38
628	HCC: The San Francisco Criteria. , 2017, , 287-291.		0
629	Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality. <i>Gastroenterology</i> , 2017, 152, 1954-1964.	1.3	185
630	Ethics and hepatitis B cure research. <i>Gut</i> , 2017, 66, 389-392.	12.1	13
631	DEB TACE for Intermediate and advanced HCC – Initial Experience in a Brazilian Cancer Center. <i>Cancer Imaging</i> , 2017, 17, 5.	2.8	15
632	Epidemiology of hepatitis B and the role of vaccination. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 239-247.	2.4	48
633	A pumpkin polysaccharide induces apoptosis by inhibiting the JAK2/STAT3 pathway in human hepatoma HepG2 cells. <i>International Journal of Biological Macromolecules</i> , 2017, 104, 681-686.	7.5	30
634	Calcium-binding protein 39 promotes hepatocellular carcinoma growth and metastasis by activating extracellular signal-regulated kinase signaling pathway. <i>Hepatology</i> , 2017, 66, 1529-1545.	7.3	52
635	Inhibition of fucosylation by 2-fluorofucose suppresses human liver cancer HepG2 cell proliferation and migration as well as tumor formation. <i>Scientific Reports</i> , 2017, 7, 11563.	3.3	61
636	A transcriptome profile in hepatocellular carcinomas based on integrated analysis of microarray studies. <i>Diagnostic Pathology</i> , 2017, 12, 4.	2.0	34
637	Stop codons in the hepatitis B surface proteins are enriched during antiviral therapy and are associated with host cell apoptosis. <i>Virology</i> , 2017, 501, 70-78.	2.4	11

#	ARTICLE	IF	CITATIONS
638	The growth inhibitory effects of garlic polysaccharide combined with cis-dichlorodiamine platinum on human HepG2 cells. <i>Biologia (Poland)</i> , 2017, 72, 1377-1384.	1.5	2
639	<i>Liver Cancer.</i> , 2017, , 438-446.		0
640	Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma. <i>Archives of Medical Science</i> , 2017, 6, 1383-1393.	0.9	17
641	Perfusion CT and PET with $^{18}\text{F}$ -FDG and $^{18}\text{F}$ -FCh in the complex diagnosis of hepatocellular carcinoma. <i>European Journal of Hybrid Imaging</i> , 2017, 1, 13.	1.5	5
642	The Role of Palliative Care in the Management of Patients with Advanced Hepatocellular Carcinoma: A Single Institution Experience. <i>Journal of Patient Care</i> , 2017, 02, .	0.1	1
643	The role of radiofrequency ablation to liver transection surface in patients with close tumor margin of HCC during hepatectomy—a case matched study. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 33-33.	3.0	2
644	Primary Liver Cancers, Part 2. <i>Cancer Control</i> , 2018, 25, 107327481774465.	1.8	16
645	Enhanced Recovery After Surgery Program for Patients Undergoing Resection of Hepatocellular Carcinoma. , 2018, , 109-127.		0
646	RNA N <sup>6</sup> -methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. <i>Hepatology</i> , 2018, 67, 2254-2270.	7.3	980
647	Laplacian normalization and bi-random walks on heterogeneous networks for predicting lncRNA-disease associations. <i>BMC Systems Biology</i> , 2018, 12, 122.	3.0	9
648	CYTOTOXIC EFFECT OF CORCHORUS DEPRESSUS AGAINST HEPG2 AND HLE HUMAN LIVER CANCER CELLS. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2018, 11, 187.	0.3	2
649	Transarterial chemoembolization with radiofrequency ablation versus hepatectomy in hepatocellular carcinoma beyond the Milan criteria: a retrospective study. <i>Cancer Management and Research</i> , 2018, Volume 10, 5545-5552.	1.9	7
650	Alternative treatment strategies to sorafenib in patients with advanced hepatocellular carcinoma: a meta-analysis of randomized Phase III trials. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5195-5201.	2.0	7
651	Prognostic significance of CD68, CD163 and Folate receptor $\beta$ positive macrophages in hepatocellular carcinoma. <i>Experimental and Therapeutic Medicine</i> , 2018, 15, 4465-4476.	1.8	49
652	Transcatheter arterial chemoembolization (TACE) combined with $\hat{I}^3$ -knife compared to TACE or $\hat{I}^3$ -knife alone for hepatocellular carcinoma. <i>Medicine (United States)</i> , 2018, 97, e10890.	1.0	2
653	Effects of Lidocaine-Mediated CPEB3 Upregulation in Human Hepatocellular Carcinoma Cell Proliferation In Vitro. <i>BioMed Research International</i> , 2018, 2018, 1-7.	1.9	11
654	MicroRNA-34a-5p inhibits liver fibrosis by regulating TGF $\beta$ 1/Smad3 pathway in hepatic stellate cells. <i>Cell Biology International</i> , 2018, 42, 1370-1376.	3.0	49
655	The innovative regularity and role of p16 methylation in blood during HCC development. <i>Journal of Cancer</i> , 2018, 9, 1925-1931.	2.5	3

#	ARTICLE	IF	CITATIONS
656	Novel insights on m6A RNA methylation in tumorigenesis: a double-edged sword. <i>Molecular Cancer</i> , 2018, 17, 101.	19.2	163
657	Evaluation of survival of patients with hepatocellular carcinoma: A comparative analysis of prognostic systems. <i>PLoS ONE</i> , 2018, 13, e0194922.	2.5	13
658	The prognostic analysis of different metastatic patterns in advanced liver cancer patients: A population based analysis. <i>PLoS ONE</i> , 2018, 13, e0200909.	2.5	8
659	Fluorescence spectroscopy as an efficient tool for staging the degree of liver fibrosis: an in vivo comparison with MRI. <i>Scientific Reports</i> , 2018, 8, 10967.	3.3	24
660	An Association Between Core Mutations in Hepatitis B Virus Genotype F1b and Hepatocellular Carcinoma in Alaskan Native People. <i>Hepatology</i> , 2019, 69, 19-33.	7.3	24
661	Hepatitis B Vaccines. , 2018, , 342-374.e17.		13
662	Perioperative exercise capacity in chronic liver injury patients with hepatocellular carcinoma undergoing hepatectomy. <i>PLoS ONE</i> , 2019, 14, e0221079.	2.5	13
663	Parathyroid hormone-related protein activates HSCs via hedgehog signalling during liver fibrosis development. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 1984-1994.	2.8	11
664	Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. <i>Nature Communications</i> , 2019, 10, 4681.	12.8	229
665	&lt;p&gt;KIAA1429 regulates the migration and invasion of hepatocellular carcinoma by altering m6A modification of ID2 mRNA&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 3421-3428.	2.0	127
666	Comparison of survival outcomes of alcohol-related hepatocellular carcinoma with or without liver cirrhosis; a ten-year experience. <i>Medicine (United States)</i> , 2019, 98, e18020.	1.0	3
667	Global scientific trends on aflatoxin research during 1998â€“2017: a bibliometric and visualized study. <i>Journal of Occupational Medicine and Toxicology</i> , 2019, 14, 27.	2.2	16
668	The histone demethylase KDM4D promotes hepatic fibrogenesis by modulating Toll-like receptor 4 signaling pathway. <i>EBioMedicine</i> , 2019, 39, 472-483.	6.1	27
669	Hepatitis viruses take advantage of traditional practices to increase the burden of hepatocellular carcinoma in Tunisia. <i>Archives of Virology</i> , 2020, 165, 33-42.	2.1	7
670	Histone chaperone FACT complex mediates oxidative stress response to promote liver cancer progression. <i>Gut</i> , 2020, 69, 329-342.	12.1	39
671	The mRNA of TCTP functions as a sponge to maintain homeostasis of TCTP protein levels in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2020, 11, 974.	6.3	4
672	Metallophosphoesterase 1, a novel candidate gene in hepatocellular carcinoma malignancy and recurrence. <i>Cancer Biology and Therapy</i> , 2020, 21, 1005-1013.	3.4	2
673	Prognostic and Clinical Implications of WNK Lysine Deficient Protein Kinase 1 Expression in Patients With Hepatocellular Carcinoma. <i>In Vivo</i> , 2020, 34, 2631-2640.	1.3	8

#	ARTICLE	IF	CITATIONS
674	Skipping of exon 10 in <i>Axl</i> pre-mRNA regulated by PTBP1 mediates invasion and metastasis process of liver cancer cells. <i>Theranostics</i> , 2020, 10, 5719-5735.	10.0	35
675	Game-Theoretical Model of Retroactive Hepatitis B Vaccination in China. <i>Bulletin of Mathematical Biology</i> , 2020, 82, 80.	1.9	16
676	&lt;p&gt;Multiple Factor Analysis of Depression and/or Anxiety in Patients with Acute Exacerbation Chronic Obstructive Pulmonary Disease&lt;/p&gt;. <i>International Journal of COPD</i> , 2020, Volume 15, 1449-1464.	2.3	16
677	The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis. <i>Molecular Cancer</i> , 2020, 19, 44.	19.2	205
678	Identification of three m6A-related mRNAs signature and risk score for the prognostication of hepatocellular carcinoma. <i>Cancer Medicine</i> , 2020, 9, 1877-1889.	2.8	60
679	Calycosin induces mitochondrial-dependent apoptosis and cell cycle arrest, and inhibits cell migration through a ROS-mediated signaling pathway in HepG2 hepatocellular carcinoma cells. <i>Toxicology in Vitro</i> , 2021, 70, 105052.	2.4	21
680	Changing Etiology and Epidemiology of Human Liver Cancer. , 2021, , 13-29.		0
681	The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 1217-1224.	1.2	8
682	Towards a Microwave Imaging System for Continuous Monitoring of Liver Tumor Ablation: Design and In Silico Validation of an Experimental Setup. <i>Diagnostics</i> , 2021, 11, 866.	2.6	10
683	Screening the genome for HCC-specific CpG methylation signatures as biomarkers for diagnosis and prognosis evaluation. <i>BMC Medical Genomics</i> , 2021, 14, 163.	1.5	2
684	Hepatocellular Carcinoma (HCC) in North-Western India: A Retrospective Study Focusing on Epidemiology, Risk Factors, and Survival. <i>Journal of Gastrointestinal Cancer</i> , 2022, 53, 921-929.	1.3	3
685	Identification of Mutation Landscape and Immune Cell Component for Liver Hepatocellular Carcinoma Highlights Potential Therapeutic Targets and Prognostic Markers. <i>Frontiers in Genetics</i> , 2021, 12, 737965.	2.3	4
686	Effectiveness of Radiofrequency Ablation for Hepatocellular Carcinomas Larger Than 3 cm in Diameter. <i>Archives of Surgery</i> , 2004, 139, 281.	2.2	73
687	Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma. , 2002, , CD003046.		18
689	Signaling Pathways in Viral Related Pre-neoplastic Liver Disease and Hepatocellular Carcinoma. , 2010, , 103-127.		1
690	Aflatoxin, Hepatitis and Worldwide Liver Cancer Risks. <i>Advances in Experimental Medicine and Biology</i> , 2002, 504, 229-233.	1.6	96
691	Screening Program in High-Risk Populations. , 2011, , 55-68.		2
692	Hepatocellular Carcinoma: Etiology and Natural History. , 2012, , 1-16.		2

#	ARTICLE	IF	CITATIONS
693	Results in Hepatocellular Carcinoma. <i>Medical Radiology</i> , 2008, , 107-115.	0.1	1
694	Liver and Bile Duct Cancer. , 2008, , 1569-1594.		1
695	Tumors and Cysts of the Liver. , 2010, , 1569-1592.e6.		3
696	Diagnosis and Monitoring of Hepatic Injury. II. Recommendations for Use of Laboratory Tests in Screening, Diagnosis, and Monitoring. <i>Clinical Chemistry</i> , 2000, 46, 2050-2068.	3.2	324
697	Hepatocellular carcinoma with a direct right atrial extension in an HCV patient previously treated with direct-acting antiviral therapy: a case report. <i>Egyptian Heart Journal</i> , 2019, 71, 5.	1.2	5
698	Enhancement of Canonical Wnt/ $\beta$ -Catenin Signaling Activity by HCV Core Protein Promotes Cell Growth of Hepatocellular Carcinoma Cells. <i>PLoS ONE</i> , 2011, 6, e27496.	2.5	109
699	Pre-S Deletion and Complex Mutations of Hepatitis B Virus Related to Young Age Hepatocellular Carcinoma in Qidong, China. <i>PLoS ONE</i> , 2013, 8, e59583.	2.5	23
700	Overexpression of Endothelin 1 Triggers Hepatocarcinogenesis in Zebrafish and Promotes Cell Proliferation and Migration through the AKT Pathway. <i>PLoS ONE</i> , 2014, 9, e85318.	2.5	64
701	The Long Noncoding RNA Expression Profile of Hepatocellular Carcinoma Identified by Microarray Analysis. <i>PLoS ONE</i> , 2014, 9, e101707.	2.5	59
702	Effect of Autologous Bone Marrow Stem Cell Therapy in Patients with Liver Cirrhosis: A Meta-analysis. <i>Journal of Clinical and Translational Hepatology</i> , 2019, 7, 1-11.	1.4	17
703	Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer. <i>Genes and Cancer</i> , 2015, 6, 317-327.	1.9	5
704	TTK activates Akt and promotes proliferation and migration of hepatocellular carcinoma cells. <i>Oncotarget</i> , 2015, 6, 34309-34320.	1.8	89
705	A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 41339-41349.	1.8	79
706	Viral hepatitis associated hepatocellular carcinoma outcomes with yttrium-90 radioembolization. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 546-552.	1.4	3
707	Expression of Maternal Embryonic Leucine Zipper Kinase (MELK) Correlates to Malignant Potentials in Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2016, 36, 5183-5188.	1.1	14
708	Anticarcinogenic Activity of Allylmercaptocaptopril Against Aflatoxin-B1 Induced Liver Carcinoma in Rats. <i>Electronic Journal of General Medicine</i> , 2011, 8, .	0.7	2
709	HCC Screening and Surveillance. , 2009, , 26-35.		1
710	Clinical Significance of Annexin A4 as a Biomarker in the Early Diagnosis of Hepatocellular Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 2661-2665.	1.2	4

#	ARTICLE	IF	CITATIONS
712	Current role of ultrasound for the management of hepatocellular carcinoma. World Journal of Gastroenterology, 2008, 14, 1710.	3.3	45
713	Liver insulin-like growth factor 2 methylation in hepatitis C virus cirrhosis and further occurrence of hepatocellular carcinoma. World Journal of Gastroenterology, 2008, 14, 5419.	3.3	21
714	TRAIL-induced apoptosis of hepatocellular carcinoma cells isaugmented by targeted therapies. World Journal of Gastroenterology, 2009, 15, 5924.	3.3	33
715	Structure analysis and expressions of a novel tetratransmembrane protein, lysosoma-associated protein transmembrane 4 $\hat{I}^2$ associated with hepatocellular carcinoma. World Journal of Gastroenterology, 2004, 10, 1555.	3.3	54
716	Mitotic cell death in BEL-7402 cells induced by enediyne antibiotic lidamycin is associated with centrosome overduplication. World Journal of Gastroenterology, 2004, 10, 2632.	3.3	9
717	Enhancement of osteopontin expression in HepG2 cells by epidermal growth factor via phosphatidylinositol 3-kinase signaling pathway. World Journal of Gastroenterology, 2004, 10, 205.	3.3	17
718	Transfection of p27 <sup>kip1</sup> enhances radiosensitivity induced by <sup>60</sup> Co $\hat{I}^3$ -irradiation in hepatocellular carcinoma HepG <sub>2</sub> cell line. World Journal of Gastroenterology, 2004, 10, 3103.	3.3	5
719	Genomic instability of murine hepatocellular carcinomas with low and high metastatic capacities. World Journal of Gastroenterology, 2004, 10, 521.	3.3	5
720	Factors for early tumor recurrence of single small hepatocellular carcinoma after percutaneous radiofrequency ablation therapy. World Journal of Gastroenterology, 2005, 11, 1439.	3.3	72
721	Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma. World Journal of Gastroenterology, 2005, 11, 2704.	3.3	36
722	Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World Journal of Gastroenterology, 2005, 11, 289.	3.3	34
723	Clinicopathological significance of loss of heterozygosity and microsatellite instability in hepatocellular carcinoma in China. World Journal of Gastroenterology, 2005, 11, 3034.	3.3	36
724	Diagnostic laparoscopy and laparoscopic ultrasonography with local anesthesia in hepatocellular carcinoma. World Journal of Gastroenterology, 2005, 11, 4120.	3.3	2
725	Hepatocellular carcinoma in Egypt: a single center study over a decade. World Journal of Gastroenterology, 2005, 11, 5193-8.	3.3	128
726	Efficacy of ultrasonography and alpha-fetoprotein on early detection of hepatocellular carcinoma. World Journal of Gastroenterology, 2006, 12, 4656.	3.3	27
727	Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World Journal of Gastroenterology, 2006, 12, 7239.	3.3	74
728	Effect of Bcl-2 and Bax on survival of side population cells from hepatocellular carcinoma cells. World Journal of Gastroenterology, 2007, 13, 6053.	3.3	23
729	Significance of hepatitis B virus surface antigen, hepatitis C virus expression in hepatocellular carcinoma and pericarcinomatous tissues. World Journal of Gastroenterology, 2007, 13, 1870.	3.3	2



#	ARTICLE	IF	CITATIONS
730	Successful initial ablation therapy contributes to survival in patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2007, 13, 1003.	3.3	21
731	<i>P16</i> gene hypermethylation and hepatocellular carcinoma: A systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2011, 17, 3043.	3.3	53
732	Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2012, 18, 1379.	3.3	39
733	Changes in survival patterns in urban Chinese patients with liver cancer. <i>World Journal of Gastroenterology</i> , 2003, 9, 1212.	3.3	8
734	Radiofrequency ablation vs. surgical resection for resectable hepatocellular carcinoma: A systematic review and meta-analysis. <i>Molecular and Clinical Oncology</i> , 2020, 12, 15-22.	1.0	11
735	Genistein potentiates the effect of 17-beta estradiol on human hepatocellular carcinoma cell line. <i>Advanced Biomedical Research</i> , 2016, 5, 133.	0.5	18
736	Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern. <i>Indian Journal of Medical Research</i> , 2019, 149, 9.	1.0	74
737	Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. <i>Journal of Carcinogenesis</i> , 2017, 16, 1.	2.5	551
738	Risk Factors in Hepatocellular Carcinoma. <i>Journal of Cancer Science &amp; Therapy</i> , 2011, 03, .	1.7	1
739	Prevention of Hepatocellular Carcinoma: Vaccination and Dietary Changes Show Promise to Eliminate Most Cases of Human Liver Cancer. <i>Journal of Carcinogenesis &amp; Mutagenesis</i> , 2012, 03, .	0.3	1
740	Racial/Ethnic Disparities in Consistent Reporting of Smoking-Related Behaviors. <i>The Journal of Addictive Behaviors</i> , 2015, 04, .	0.2	18
741	Multi-Detector-Row CT Diagnosis of Adrenal Incidentaloma in Patients with Hepatocellular Carcinoma. <i>Advances in Computed Tomography</i> , 2013, 02, 34-40.	0.3	2
742	Epidemiologic and Clinicopathologic Features of Advanced Hepatocellular Carcinoma. <i>Journal of Cancer Therapy</i> , 2019, 10, 411-421.	0.4	1
743	Recent insights on risk factors of hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2009, 1, 3.	2.0	16
744	Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2010, 2, 114.	2.0	42
745	Role of radiofrequency ablation in the treatment of small hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2010, 2, 146.	2.0	11
746	Hepatitis C virus inhibitor synergism suggests multistep interactions between heat-shock protein 90 and hepatitis C virus replication. <i>World Journal of Hepatology</i> , 2016, 8, 282.	2.0	1
749	Prediction of Complete Necrosis of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Prior to Liver Transplantation. <i>Gut and Liver</i> , 2009, 3, 285-291.	2.9	16

#	ARTICLE	IF	CITATIONS
750	Saudi Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: Technical Review and Practice Guidelines. <i>Annals of Saudi Medicine</i> , 2012, 32, 174-199.	1.1	26
751	Molecular approach to treatment of hepatocellular carcinoma: new hope for therapeutic targets. <i>Journal of Experimental and Integrative Medicine</i> , 2011, 1, 83.	0.1	3
752	Decreased Diethylnitrosamine-induced Liver Preneoplastic Lesions by Estradiol-3-benzoate Treatment. <i>Toxicological Research</i> , 2011, 27, 247-251.	2.1	1
753	Loco-regional therapies for patients with hepatocellular carcinoma awaiting liver transplantation: Selecting an optimal therapy. <i>World Journal of Transplantation</i> , 2016, 6, 306.	1.6	17
754	Leading Health Risks, Diseases And Causes Of Mortality Among Hispanics In United States Of America (USA). <i>The Internet Journal of Health</i> , 2008, 8, .	0.1	3
755	Recurrence after Anatomic Resection Versus Nonanatomic Resection for Hepatocellular Carcinoma: A Meta-analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 1771-1777.	1.2	29
756	Anti-tumor Efficacy of a Hepatocellular Carcinoma Vaccine Based on Dendritic Cells Combined with Tumor-derived Autophagosomes in Murine Models. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 3109-3116.	1.2	25
757	Retrospective Evaluation of Discrepancies between Radiological and Pathological Size of Hepatocellular Carcinoma Masses. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 9487-9494.	1.2	4
758	Multicenter Epidemiologic Study on Hepatocellular Carcinoma in Turkey. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 2923-2927.	1.2	20
759	Risk of development of hepatocellular carcinoma in patients with NASH-related cirrhosis. <i>Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation</i> , 2013, 34, 159-163.	0.0	29
760	Hypoxia blocks ferroptosis of hepatocellular carcinoma via suppression of METTL14 triggered YTHDF2-dependent silencing of SLC7A11. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 10197-10212.	3.6	73
762	HepatozellulÄres Karzinom. , 2002, , 207-229.		0
763	Infections and the Etiology of Human Cancer: Epidemiological Evidence and Opportunities for Prevention. <i>Handbook of Experimental Pharmacology</i> , 2003, , 229-251.	1.8	0
764	Chronic inflammation and cancer in various organ systems. , 2004, , 1-20.		1
765	Algoritmo diagnÃ³stico y terapÃ©utico del carcinoma hepatocelular. <i>Oncologia</i> , 2004, 27, .	0.0	0
766	The Effect of Neem ( <i>Azadirachta indica</i> ) Aqueous Extract and Dietary Selenium on Distribution of Selenium in Liver Tissue During Hepatocarcinogenesis. <i>Journal of Biological Sciences</i> , 2004, 4, 584-587.	0.3	0
767	The Surgeonâ€™s Perspective on Hepatic Radiofrequency Ablation. , 2005, , 480-488.		0
768	Diseases of the Liver and Alimentary Tract. , 2006, , 655-710.		0

#	ARTICLE	IF	CITATIONS
769	Diseases of the Liver and Alimentary Tract. , 2006, , 655-710.		0
770	Current status on the interaction of testosterone and estradiol with liver cirrhosis. World Chinese Journal of Digestology, 2006, 14, 3397.	0.1	0
771	Radiological response in Saudi patients undergoing transarterial chemoembolization for hepatocellular carcinoma. Saudi Journal of Gastroenterology, 2007, 13, 21.	1.1	1
772	Environmental Carcinogens and Risk for Human Liver Cancer. , 2009, , 27-53.		0
773	Screening and Biomarkers for Hepatocellular Carcinoma. , 2009, , 327-348.		0
774	Resection of Hepatocellular Carcinoma. , 2009, , 453-465.		0
775	Hepatocellular Carcinoma: Overexpression of Homeoprotein Six1 as a Marker for Predicting Survival. , 2009, , 313-323.		0
776	Enhanced Protein Expression of Signal Transducer and Activator of Transcription 3 and Protein Kinase Substrate p36 in Hepatocellular Carcinoma. Korean Journal of Pathology, 2009, 43, 393.	1.3	0
777	Tropical Gastroenterological Problems. , 2009, , 107-141.		2
779	The Expression of Apolipoprotein D in Hepatocellular Carcinoma. Korean Journal of Pathology, 2010, 44, 187.	1.3	0
780	Epidemiologie, Ätiologie und Pathogenese. , 2010, , 14-37.		0
781	Stereotactic Body Radiation Therapy. , 2010, , 1594-1600.		0
782	Preoperative Imaging of Liver Cancers: Hepatocellular Carcinoma. , 2011, , 51-59.		0
783	Facteur de risque et d'impactage du carcinome h'epatocellulaire. Bulletin De L'Academie Nationale De Medecine, 2012, 196, 85-96.	0.0	0
784	Regulation of Innate Immunity and Interferon Defenses by Hepatitis C Virus. , 2012, , 245-269.		0
785	Roles of Ethnicity in Survival of Hepatocellular Carcinoma Patients in Malaysia. Asian Pacific Journal of Cancer Prevention, 2012, 13, 6023-6026.	1.2	2
786	Selective transitional zone sampling approach versus random biopsy in cases with malignant liver masses: Is there any superiority?. Turkish Journal of Gastroenterology, 2012, 23, 708-713.	1.1	0
787	Renin Angiotensin System and Hepatic Malignancy. Pharmacologia, 2013, 4, 327-334.	0.3	0

#	ARTICLE	IF	CITATIONS
788	MAGE Genes mRNAs: Potential Early Diagnostic Markers for Hepatocellular Carcinoma in HCV Saudi Patients. IOSR Journal of Dental and Medical Sciences, 2014, 13, 61-65.	0.0	0
789	Cytotoxicity of Nutritional Supplement Galaxy <sup>®</sup> against HepG2 Hepatocellular Carcinoma. Alternative & Integrative Medicine, 2014, 03, .	0.1	0
790	Assessment of Lens Culinaris Agglutinin-Reactive Fraction of Alpha Fetoprotein as an Early Diagnostic Marker for Hepatocellular Carcinoma among Sudanese Patients with Chronic Liver Disease. Cancer and Oncology Research, 2014, 2, 1-6.	0.2	1
792	Platelet Count and INR Profile after Hepatic Resection in Cirrhotic Patients: Implications for Epidural Analgesia. International Journal of Anesthetics and Anesthesiology, 2014, 1, .	0.2	0
793	Application of Tumor Biomarkers as Screening Tools in Early Detection of Hepatocellular Carcinoma. Gene, Cell and Tissue, 2015, 2, .	0.2	0
794	HCC: The San Francisco Criteria. , 2016, , 1-5.		0
795	HCC: The San Francisco Criteria. , 2016, , 1-5.		0
796	21.ÂChronic Liver Disease. , 2016, , .		0
797	Liver Tumors. Pediatric Oncology, 2017, , 453-476.	0.5	0
798	Malignant Liver Lesions. , 2017, , 71-88.		0
799	Đ;Đ°Ñ€Đ,Đ1/2Ñ–Đ1/2Đ³ Ñ– Ñ€Đ°Đ1/2Đ1/2Ñ•ĐÑ–Đ°Đ³Đ1/2Đ³/4ÑÑ,Đ,Đ°Đ° Đ³ĐµĐ;Đ°Ñ,Đ³/4Ñ†ĐµĐ»ÑŽĐ»ÑÑ€Đ1/2Đ³/4Ñ2– Đ°Đ°Ñ€Ñ†Đ,Đ1/2		0
801	Rate and Predictive Factors for Sustained Complete Response after Selective Transarterial Chemoembolization (TACE) in Patients with Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention, 2018, 19, 3545-3550.	1.2	18
803	Multiparametric Ultrasound in the Diagnosis of Hepatocellular Carcinoma in Patients without Cirrhosis (Clinical Case). Journal of Oncology Diagnostic Radiology and Radiotherapy, 2020, 3, 86-93.	0.2	0
804	Clinical Strategies for Chemoprevention of Liver Cancer. , 2005, , 503-516.		0
805	Liver Tumors. , 2007, , 311-330.		0
806	Comparison between Computer Tomography and Magnetic Resonance Imaging in the Diagnosis of Small Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention, 2016, 17, 4805-4811.	1.2	3
807	Recent developments in the first detection of hepatocellular carcinoma. Clinical Biochemist Reviews, 2005, 26, 65-79.	3.3	39
808	A Phase II Study of Long-Acting Octreotide in Patients With Advanced Hepatocellular Carcinoma and CLIP Score of 3 or Higher. Gastrointestinal Cancer Research: GCR, 2009, 3, 45-8.	0.7	5

#	ARTICLE	IF	CITATIONS
809	Screening for hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , 2008, 4, 201-8.	0.1	5
810	Cirrhosis and Chronic Viral Hepatitis as Risk Factors for Hepatocellular Carcinoma: Romanian Single-clinic Experience. <i>MĂJ dca</i> , 2010, 5, 265-70.	0.1	6
811	Hepatocellular carcinoma in the world and the middle East. <i>Middle East Journal of Digestive Diseases</i> , 2010, 2, 31-41.	0.4	36
812	MicroRNA-338-3p inhibits cell proliferation in hepatocellular carcinoma by target forkhead box P4 (FOXP4). <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 337-44.	0.5	40
813	Risk factors for naturally-occurring early-onset hepatocellular carcinoma in patients with HBV-associated liver cirrhosis in China. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 1205-12.	1.3	14
815	Protein-protein interaction network analysis of cirrhosis liver disease. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2016, 9, 114-23.	0.6	43
816	Evaluation of liver cirrhosis and hepatocellular carcinoma using Protein-Protein Interaction Networks. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2016, 9, S14-S22.	0.6	19
817	Low expression is associated with poor prognosis in patients with hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2017, 7, 2465-2477.	1.4	5
818	JUB induces epithelial-mesenchymal transition via the Wnt/ $\beta$ 2-catenin signaling pathway in hepatocellular carcinoma cells. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 1374-1382.	0.5	1
819	Decreased cytoplasmic expression of Raptor correlates with disease progression and unfavorable prognosis in hepatocellular carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2017, 10, 11789-11796.	0.5	0
820	Increased risk of hepatocellular carcinoma in patients with traumatic liver injury. <i>Medicine (United Tj ETQqO O O rgBT/Overlock 10 Tf 50</i>	1.0	3
821	Hepatocellular carcinomaâ€”An updated review. , 2022, , 11-31.		0
822	Mechanism Analysis of LINC00665 and Its Peptides CIP2A-BP in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 861096.	2.3	8
823	Update on perioperative management of patients undergoing surgery for liver cancer. <i>Annals of Gastroenterological Surgery</i> , 0, , .	2.4	2
826	Management of liver cirrhosis in patients with hepatocellular carcinoma. <i>Chinese Clinical Oncology</i> , 2013, 2, 34.	1.2	5
827	Liver Transplantation in Hepatocellular Carcinoma: Experiences from the Shiraz Transplant Center.. <i>International Journal of Organ Transplantation Medicine</i> , 2021, 12, 9-19.	0.5	0
828	Curing of liver cancer: an update on the efficacy of bioactive compounds. , 2022, , 81-92.		0
829	Medicinal Plants for the Treatment of Liver Cancer. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2022, , 232-248.	0.1	0

#	ARTICLE	IF	CITATIONS
830	Safety and oncological benefits of hepatectomy for hepatocellular carcinoma in octogenarians. <i>Asian Journal of Surgery</i> , 2023, 46, 366-372.	0.4	0
831	Cytochrome P450 family members CYP2E1, CYP3A4, and CYP1A2 are related to prognosis of HCC and can be used as molecular markers for its diagnosis. <i>World Chinese Journal of Digestology</i> , 2022, 30, 402-410.	0.1	0
832	The Serum Hepatitis B Virus Large Surface Protein as High-Risk Recurrence Biomarker for Hepatoma after Curative Surgery. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5376.	4.1	4
833	Article Commentary: Can Antiviral Therapy for Chronic Hepatitis B Enhance the Progression to Hepatocellular Carcinoma?. <i>Antiviral Therapy</i> , 2009, 14, 139-142.	1.0	10
834	Riboflavin ameliorates mitochondrial dysfunction via the AMPK/PGC1 $\alpha$ /HO $\alpha$ 1 signaling pathway and attenuates carbon tetrachloride-induced liver fibrosis in rats. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	1.8	5
835	The role of RNA modification in hepatocellular carcinoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	6
836	Possibility of Liver Cancer Treatment By Nanoformulation of Phenolic Phytochemicals. <i>Current Nanomedicine</i> , 2022, 12, 108-125.	0.6	1
837	Establishment and validation of a novel prognostic model for non-virus-related hepatocellular carcinoma. <i>Cancer Cell International</i> , 2022, 22, .	4.1	4
839	Mortality from primary liver cancer in Switzerland from 1975 to 1994. <i>Swiss Medical Weekly</i> , 0, , .	1.6	3
840	Multi-Omics Data Analysis for Cancer Research: Colorectal Cancer, Liver Cancer and Lung Cancer. <i>Translational Bioinformatics</i> , 2023, , 77-99.	0.0	0
841	Investigaci3n b3sica sobre hepatocarcinoma en la Universidad de Le3n. <i>Ambiociencias</i> , 0, , 39-56.	0.0	0
842	Diagnosis and management of hepatocellular carcinoma. <i>Saudi Journal of Gastroenterology</i> , 2007, 13, 1.	1.1	2
843	Saponins in the Treatment of Gastrointestinal Tract Cancer. , 2023, , 159-181.		0
844	SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma. <i>IScience</i> , 2023, 26, 106994.	4.1	0
845	Standardized Phantoms. <i>Lecture Notes in Bioengineering</i> , 2023, , 1-32.	0.4	1
846	Clinical Practice Guidelines For the Management of Hepatocellular Carcinoma: A Systematic Review. <i>Journal of Gastrointestinal Cancer</i> , 0, , .	1.3	0
847	Hepatitis B Vaccines. , 2023, , 389-432.e21.		0
848	Near infrared-emitting multimodal nanosystem for in vitro magnetic hyperthermia of hepatocellular carcinoma and dual imaging of in vivo liver fibrosis. <i>Scientific Reports</i> , 2023, 13, .	3.3	0

#	ARTICLE	IF	CITATIONS
850	Sappanone A Alleviates the Severity of Carbon Tetrachloride-Induced Liver Fibrosis in Mice. Antioxidants, 2023, 12, 1718.	5.1	0
851	Chromosome Y. , 2023, , 366-382.		0